
No change: table 0 2 8
  First character (Section) is value 0: Medical and Surgical
  Second character (Body System) is value 2: Heart and Great Vessels
  Third character (Operation) is value 8: Division: Cutting into a body part, without draining fluids and/or gases from the body part, in order to separate or transect a body part

No change: First panel of table 0 2 8
  Fourth character (Body Part) has 3 choices.
    First choice is value 8: Conduction Mechanism
    Second choice is value 9: Chordae Tendineae
    Third choice is value D: Papillary Muscle
  Fifth character (Approach) has 3 choices.
    First choice is value 0: Open
    Second choice is value 3: Percutaneous
    Third choice is value 4: Percutaneous Endoscopic
  Sixth character (Device) is value Z: No Device
  Seventh character (Qualifier) is value Z: No Qualifier

FY2027: Second panel of table 0 2 8
  Fourth character (Body Part) has 2 choices.
    First choice is value F: Aortic Valve
    Second choice is value G: Mitral Valve
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device) is value Z: No Device
  Seventh character (Qualifier) has 2 choices.
    First choice is value 0: Native Leaflet
    Second choice is value 1: Prosthetic Leaflet

No change: table 0 R G
  First character (Section) is value 0: Medical and Surgical
  Second character (Body System) is value R: Upper Joints
  Third character (Operation) is value G: Fusion: Joining together portions of an articular body part rendering the articular body part immobile

FY2027: First panel of table 0 R G
  Fourth character (Body Part) has 7 choices.
    First choice is value 0: Occipital-cervical Joint
    Second choice is value 1: Cervical Vertebral Joint
    Third choice is value 2: Cervical Vertebral Joints, 2 or more
    Fourth choice is value 4: Cervicothoracic Vertebral Joint
    Fifth choice is value 6: Thoracic Vertebral Joint
    Sixth choice is value 7: Thoracic Vertebral Joints, 2 to 7
    Seventh choice is value 8: Thoracic Vertebral Joints, 8 or more
  Fifth character (Approach) has 3 choices.
    First choice is value 0: Open
    Second choice is value 3: Percutaneous
    Third choice is value 4: Percutaneous Endoscopic
  Sixth character (Device) has 3 choices.
    First choice is value 7: Autologous Tissue Substitute
    Second choice is value J: Synthetic Substitute
    Third choice is value K: Nonautologous Tissue Substitute
  Seventh character (Qualifier) has 3 choices.
    First choice is value 0: Anterior Approach, Anterior Column
    Second choice is value 1: Posterior Approach, Posterior Column
    Third choice is value J: Posterior Approach, Anterior Column

FY2027: Second panel of table 0 R G
  Fourth character (Body Part) has 7 choices.
    First choice is value 0: Occipital-cervical Joint
    Second choice is value 1: Cervical Vertebral Joint
    Third choice is value 2: Cervical Vertebral Joints, 2 or more
    Fourth choice is value 4: Cervicothoracic Vertebral Joint
    Fifth choice is value 6: Thoracic Vertebral Joint
    Sixth choice is value 7: Thoracic Vertebral Joints, 2 to 7
    Seventh choice is value 8: Thoracic Vertebral Joints, 8 or more
  Fifth character (Approach) has 3 choices.
    First choice is value 0: Open
    Second choice is value 3: Percutaneous
    Third choice is value 4: Percutaneous Endoscopic
  Sixth character (Device) is value A: Interbody Fusion Device
  Seventh character (Qualifier) has 2 choices.
    First choice is value 0: Anterior Approach, Anterior Column
    Second choice is value J: Posterior Approach, Anterior Column

FY2027: Third panel of table 0 R G
  Fourth character (Body Part) is value A: Thoracolumbar Vertebral Joint
  Fifth character (Approach) has 3 choices.
    First choice is value 0: Open
    Second choice is value 3: Percutaneous
    Third choice is value 4: Percutaneous Endoscopic
  Sixth character (Device) has 3 choices.
    First choice is value 7: Autologous Tissue Substitute
    Second choice is value J: Synthetic Substitute
    Third choice is value K: Nonautologous Tissue Substitute
  Seventh character (Qualifier) has 3 choices.
    First choice is value 0: Anterior Approach, Anterior Column
    Second choice is value 1: Posterior Approach, Posterior Column
    Third choice is value J: Posterior Approach, Anterior Column

FY2027: Fourth panel of table 0 R G
  Fourth character (Body Part) is value A: Thoracolumbar Vertebral Joint
  Fifth character (Approach) has 3 choices.
    First choice is value 0: Open
    Second choice is value 3: Percutaneous
    Third choice is value 4: Percutaneous Endoscopic
  Sixth character (Device) has 2 choices.
    First choice is value A: Interbody Fusion Device
    Second choice is value E: Interbody Fusion Device, Custom-Made Anatomically and Virtually Designed
  Seventh character (Qualifier) has 2 choices.
    First choice is value 0: Anterior Approach, Anterior Column
    Second choice is value J: Posterior Approach, Anterior Column

No change: Fifth panel of table 0 R G
  Fourth character (Body Part) has 8 choices.
    First choice is value C: Temporomandibular Joint, Right
    Second choice is value D: Temporomandibular Joint, Left
    Third choice is value E: Sternoclavicular Joint, Right
    Fourth choice is value F: Sternoclavicular Joint, Left
    Fifth choice is value G: Acromioclavicular Joint, Right
    Sixth choice is value H: Acromioclavicular Joint, Left
    Seventh choice is value J: Shoulder Joint, Right
    Eighth choice is value K: Shoulder Joint, Left
  Fifth character (Approach) has 3 choices.
    First choice is value 0: Open
    Second choice is value 3: Percutaneous
    Third choice is value 4: Percutaneous Endoscopic
  Sixth character (Device) has 4 choices.
    First choice is value 4: Internal Fixation Device
    Second choice is value 7: Autologous Tissue Substitute
    Third choice is value J: Synthetic Substitute
    Fourth choice is value K: Nonautologous Tissue Substitute
  Seventh character (Qualifier) is value Z: No Qualifier

No change: Sixth panel of table 0 R G
  Fourth character (Body Part) has 12 choices.
    First choice is value L: Elbow Joint, Right
    Second choice is value M: Elbow Joint, Left
    Third choice is value N: Wrist Joint, Right
    Fourth choice is value P: Wrist Joint, Left
    Fifth choice is value Q: Carpal Joint, Right
    Sixth choice is value R: Carpal Joint, Left
    Seventh choice is value S: Carpometacarpal Joint, Right
    Eighth choice is value T: Carpometacarpal Joint, Left
    Ninth choice is value U: Metacarpophalangeal Joint, Right
    Tenth choice is value V: Metacarpophalangeal Joint, Left
    Eleventh choice is value W: Finger Phalangeal Joint, Right
    Twelfth choice is value X: Finger Phalangeal Joint, Left
  Fifth character (Approach) has 3 choices.
    First choice is value 0: Open
    Second choice is value 3: Percutaneous
    Third choice is value 4: Percutaneous Endoscopic
  Sixth character (Device) has 6 choices.
    First choice is value 3: Internal Fixation Device, Sustained Compression
    Second choice is value 4: Internal Fixation Device
    Third choice is value 5: External Fixation Device
    Fourth choice is value 7: Autologous Tissue Substitute
    Fifth choice is value J: Synthetic Substitute
    Sixth choice is value K: Nonautologous Tissue Substitute
  Seventh character (Qualifier) is value Z: No Qualifier

No change: table 0 S G
  First character (Section) is value 0: Medical and Surgical
  Second character (Body System) is value S: Lower Joints
  Third character (Operation) is value G: Fusion: Joining together portions of an articular body part rendering the articular body part immobile

No change: First panel of table 0 S G
  Fourth character (Body Part) has 3 choices.
    First choice is value 0: Lumbar Vertebral Joint
    Second choice is value 1: Lumbar Vertebral Joints, 2 or more
    Third choice is value 3: Lumbosacral Joint
  Fifth character (Approach) has 3 choices.
    First choice is value 0: Open
    Second choice is value 3: Percutaneous
    Third choice is value 4: Percutaneous Endoscopic
  Sixth character (Device) has 3 choices.
    First choice is value 7: Autologous Tissue Substitute
    Second choice is value J: Synthetic Substitute
    Third choice is value K: Nonautologous Tissue Substitute
  Seventh character (Qualifier) has 3 choices.
    First choice is value 0: Anterior Approach, Anterior Column
    Second choice is value 1: Posterior Approach, Posterior Column
    Third choice is value J: Posterior Approach, Anterior Column

FY2027: Second panel of table 0 S G
  Fourth character (Body Part) has 3 choices.
    First choice is value 0: Lumbar Vertebral Joint
    Second choice is value 1: Lumbar Vertebral Joints, 2 or more
    Third choice is value 3: Lumbosacral Joint
  Fifth character (Approach) has 3 choices.
    First choice is value 0: Open
    Second choice is value 3: Percutaneous
    Third choice is value 4: Percutaneous Endoscopic
  Sixth character (Device) has 2 choices.
    First choice is value A: Interbody Fusion Device
    Second choice is value E: Interbody Fusion Device, Custom-Made Anatomically and Virtually Designed
  Seventh character (Qualifier) has 2 choices.
    First choice is value 0: Anterior Approach, Anterior Column
    Second choice is value J: Posterior Approach, Anterior Column

No change: Third panel of table 0 S G
  Fourth character (Body Part) has 3 choices.
    First choice is value 5: Sacrococcygeal Joint
    Second choice is value 7: Sacroiliac Joint, Right
    Third choice is value 8: Sacroiliac Joint, Left
  Fifth character (Approach) has 3 choices.
    First choice is value 0: Open
    Second choice is value 3: Percutaneous
    Third choice is value 4: Percutaneous Endoscopic
  Sixth character (Device) has 4 choices.
    First choice is value 4: Internal Fixation Device
    Second choice is value 7: Autologous Tissue Substitute
    Third choice is value J: Synthetic Substitute
    Fourth choice is value K: Nonautologous Tissue Substitute
  Seventh character (Qualifier) is value Z: No Qualifier

No change: Fourth panel of table 0 S G
  Fourth character (Body Part) has 14 choices.
    First choice is value 9: Hip Joint, Right
    Second choice is value B: Hip Joint, Left
    Third choice is value C: Knee Joint, Right
    Fourth choice is value D: Knee Joint, Left
    Fifth choice is value F: Ankle Joint, Right
    Sixth choice is value G: Ankle Joint, Left
    Seventh choice is value H: Tarsal Joint, Right
    Eighth choice is value J: Tarsal Joint, Left
    Ninth choice is value K: Tarsometatarsal Joint, Right
    Tenth choice is value L: Tarsometatarsal Joint, Left
    Eleventh choice is value M: Metatarsal-Phalangeal Joint, Right
    Twelfth choice is value N: Metatarsal-Phalangeal Joint, Left
    Thirteenth choice is value P: Toe Phalangeal Joint, Right
    Fourteenth choice is value Q: Toe Phalangeal Joint, Left
  Fifth character (Approach) has 3 choices.
    First choice is value 0: Open
    Second choice is value 3: Percutaneous
    Third choice is value 4: Percutaneous Endoscopic
  Sixth character (Device) has 6 choices.
    First choice is value 3: Internal Fixation Device, Sustained Compression
    Second choice is value 4: Internal Fixation Device
    Third choice is value 5: External Fixation Device
    Fourth choice is value 7: Autologous Tissue Substitute
    Fifth choice is value J: Synthetic Substitute
    Sixth choice is value K: Nonautologous Tissue Substitute
  Seventh character (Qualifier) is value Z: No Qualifier

No change: table 0 W 9
  First character (Section) is value 0: Medical and Surgical
  Second character (Body System) is value W: Anatomical Regions, General
  Third character (Operation) is value 9: Drainage: Taking or letting out fluids and/or gases from a body part

FY2027: First panel of table 0 W 9
  Fourth character (Body Part) has 15 choices.
    First choice is value 0: Head
    Second choice is value 1: Cranial Cavity
    Third choice is value 2: Face
    Fourth choice is value 3: Oral Cavity and Throat
    Fifth choice is value 4: Upper Jaw
    Sixth choice is value 5: Lower Jaw
    Seventh choice is value 8: Chest Wall
    Eighth choice is value D: Pericardial Cavity
    Ninth choice is value F: Abdominal Wall
    Tenth choice is value G: Peritoneal Cavity
    Eleventh choice is value H: Retroperitoneum
    Twelfth choice is value K: Upper Back
    Thirteenth choice is value L: Lower Back
    Fourteenth choice is value M: Perineum, Male
    Fifteenth choice is value N: Perineum, Female
  Fifth character (Approach) has 3 choices.
    First choice is value 0: Open
    Second choice is value 3: Percutaneous
    Third choice is value 4: Percutaneous Endoscopic
  Sixth character (Device) is value 0: Drainage Device
  Seventh character (Qualifier) is value Z: No Qualifier

FY2027: Second panel of table 0 W 9
  Fourth character (Body Part) has 15 choices.
    First choice is value 0: Head
    Second choice is value 1: Cranial Cavity
    Third choice is value 2: Face
    Fourth choice is value 3: Oral Cavity and Throat
    Fifth choice is value 4: Upper Jaw
    Sixth choice is value 5: Lower Jaw
    Seventh choice is value 8: Chest Wall
    Eighth choice is value D: Pericardial Cavity
    Ninth choice is value F: Abdominal Wall
    Tenth choice is value G: Peritoneal Cavity
    Eleventh choice is value H: Retroperitoneum
    Twelfth choice is value K: Upper Back
    Thirteenth choice is value L: Lower Back
    Fourteenth choice is value M: Perineum, Male
    Fifteenth choice is value N: Perineum, Female
  Fifth character (Approach) has 3 choices.
    First choice is value 0: Open
    Second choice is value 3: Percutaneous
    Third choice is value 4: Percutaneous Endoscopic
  Sixth character (Device) is value Z: No Device
  Seventh character (Qualifier) has 2 choices.
    First choice is value X: Diagnostic
    Second choice is value Z: No Qualifier

No change: Third panel of table 0 W 9
  Fourth character (Body Part) has 2 choices.
    First choice is value 6: Neck
    Second choice is value J: Pelvic Cavity
  Fifth character (Approach) has 5 choices.
    First choice is value 0: Open
    Second choice is value 3: Percutaneous
    Third choice is value 4: Percutaneous Endoscopic
    Fourth choice is value 7: Via Natural or Artificial Opening
    Fifth choice is value 8: Via Natural or Artificial Opening Endoscopic
  Sixth character (Device) is value 0: Drainage Device
  Seventh character (Qualifier) is value Z: No Qualifier

No change: Fourth panel of table 0 W 9
  Fourth character (Body Part) has 2 choices.
    First choice is value 6: Neck
    Second choice is value J: Pelvic Cavity
  Fifth character (Approach) has 5 choices.
    First choice is value 0: Open
    Second choice is value 3: Percutaneous
    Third choice is value 4: Percutaneous Endoscopic
    Fourth choice is value 7: Via Natural or Artificial Opening
    Fifth choice is value 8: Via Natural or Artificial Opening Endoscopic
  Sixth character (Device) is value Z: No Device
  Seventh character (Qualifier) has 2 choices.
    First choice is value X: Diagnostic
    Second choice is value Z: No Qualifier

FY2027: Fifth panel of table 0 W 9
  Fourth character (Body Part) has 3 choices.
    First choice is value 9: Pleural Cavity, Right
    Second choice is value B: Pleural Cavity, Left
    Third choice is value C: Mediastinum
  Fifth character (Approach) has 3 choices.
    First choice is value 0: Open
    Second choice is value 3: Percutaneous
    Third choice is value 4: Percutaneous Endoscopic
  Sixth character (Device) is value 0: Drainage Device
  Seventh character (Qualifier) has 2 choices.
    First choice is value 3: Active Mechanical Clearance
    Second choice is value Z: No Qualifier

FY2027: Sixth panel of table 0 W 9
  Fourth character (Body Part) has 3 choices.
    First choice is value 9: Pleural Cavity, Right
    Second choice is value B: Pleural Cavity, Left
    Third choice is value C: Mediastinum
  Fifth character (Approach) has 3 choices.
    First choice is value 0: Open
    Second choice is value 3: Percutaneous
    Third choice is value 4: Percutaneous Endoscopic
  Sixth character (Device) is value Z: No Device
  Seventh character (Qualifier) has 2 choices.
    First choice is value X: Diagnostic
    Second choice is value Z: No Qualifier

No change: table 3 0 2
  First character (Section) is value 3: Administration
  Second character (Body System) is value 0: Circulatory
  Third character (Operation) is value 2: Transfusion: Putting in blood or blood products

No change: First panel of table 3 0 2
  Fourth character (Body System / Region) has 2 choices.
    First choice is value 3: Peripheral Vein
    Second choice is value 4: Central Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) is value C: Hematopoietic Stem/Progenitor Cells, Genetically Modified
  Seventh character (Qualifier) is value 0: Autologous

No change: Second panel of table 3 0 2
  Fourth character (Body System / Region) has 2 choices.
    First choice is value 3: Peripheral Vein
    Second choice is value 4: Central Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) is value D: Pathogen Reduced Cryoprecipitated Fibrinogen Complex
  Seventh character (Qualifier) is value 1: Nonautologous

No change: Third panel of table 3 0 2
  Fourth character (Body System / Region) has 2 choices.
    First choice is value 3: Peripheral Vein
    Second choice is value 4: Central Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) has 3 choices.
    First choice is value G: Bone Marrow
    Second choice is value X: Stem Cells, Cord Blood
    Third choice is value Y: Stem Cells, Hematopoietic
  Seventh character (Qualifier) has 4 choices.
    First choice is value 0: Autologous
    Second choice is value 2: Allogeneic, Related
    Third choice is value 3: Allogeneic, Unrelated
    Fourth choice is value 4: Allogeneic, Unspecified

FY2027: Fourth panel of table 3 0 2
  Fourth character (Body System / Region) has 2 choices.
    First choice is value 3: Peripheral Vein
    Second choice is value 4: Central Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) has 12 choices.
    First choice is value H: Whole Blood
    Second choice is value J: Serum Albumin
    Third choice is value K: Frozen Plasma
    Fourth choice is value L: Fresh Plasma
    Fifth choice is value M: Plasma Cryoprecipitate
    Sixth choice is value N: Red Blood Cells
    Seventh choice is value P: Frozen Red Cells
    Eighth choice is value Q: White Cells
    Ninth choice is value R: Platelets
    Tenth choice is value T: Fibrinogen
    Eleventh choice is value V: Antihemophilic Factors
    Twelfth choice is value W: Factor IX
  Seventh character (Qualifier) has 2 choices.
    First choice is value 0: Autologous
    Second choice is value 1: Nonautologous

FY2027: Fifth panel of table 3 0 2
  Fourth character (Body System / Region) has 2 choices.
    First choice is value 3: Peripheral Vein
    Second choice is value 4: Central Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) is value S: Globulin
  Seventh character (Qualifier) has 3 choices.
    First choice is value 0: Autologous
    Second choice is value 1: Nonautologous
    Third choice is value 5: Immune Globulin, High-Dose

No change: Sixth panel of table 3 0 2
  Fourth character (Body System / Region) has 2 choices.
    First choice is value 3: Peripheral Vein
    Second choice is value 4: Central Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) is value U: Stem Cells, T-cell Depleted Hematopoietic
  Seventh character (Qualifier) has 3 choices.
    First choice is value 2: Allogeneic, Related
    Second choice is value 3: Allogeneic, Unrelated
    Third choice is value 4: Allogeneic, Unspecified

No change: Seventh panel of table 3 0 2
  Fourth character (Body System / Region) is value 7: Products of Conception, Circulatory
  Fifth character (Approach) has 2 choices.
    First choice is value 3: Percutaneous
    Second choice is value 7: Via Natural or Artificial Opening
  Sixth character (Substance) has 13 choices.
    First choice is value H: Whole Blood
    Second choice is value J: Serum Albumin
    Third choice is value K: Frozen Plasma
    Fourth choice is value L: Fresh Plasma
    Fifth choice is value M: Plasma Cryoprecipitate
    Sixth choice is value N: Red Blood Cells
    Seventh choice is value P: Frozen Red Cells
    Eighth choice is value Q: White Cells
    Ninth choice is value R: Platelets
    Tenth choice is value S: Globulin
    Eleventh choice is value T: Fibrinogen
    Twelfth choice is value V: Antihemophilic Factors
    Thirteenth choice is value W: Factor IX
  Seventh character (Qualifier) is value 1: Nonautologous

No change: Eighth panel of table 3 0 2
  Fourth character (Body System / Region) is value 8: Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) is value B: 4-Factor Prothrombin Complex Concentrate
  Seventh character (Qualifier) is value 1: Nonautologous

No change: Ninth panel of table 3 0 2
  Fourth character (Body System / Region) is value A: Bone Marrow
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) has 7 choices.
    First choice is value H: Whole Blood
    Second choice is value J: Serum Albumin
    Third choice is value K: Frozen Plasma
    Fourth choice is value L: Fresh Plasma
    Fifth choice is value N: Red Blood Cells
    Sixth choice is value P: Frozen Red Cells
    Seventh choice is value R: Platelets
  Seventh character (Qualifier) has 2 choices.
    First choice is value 0: Autologous
    Second choice is value 1: Nonautologous

No change: table 3 E 0
  First character (Section) is value 3: Administration
  Second character (Body System) is value E: Physiological Systems and Anatomical Regions
  Third character (Operation) is value 0: Introduction: Putting in or on a therapeutic, diagnostic, nutritional, physiological, or prophylactic substance except blood or blood products

No change: First panel of table 3 E 0
  Fourth character (Body System / Region) is value 0: Skin and Mucous Membranes
  Fifth character (Approach) is value X: External
  Sixth character (Substance) is value 0: Antineoplastic
  Seventh character (Qualifier) has 2 choices.
    First choice is value 5: Other Antineoplastic
    Second choice is value M: Monoclonal Antibody

No change: Second panel of table 3 E 0
  Fourth character (Body System / Region) is value 0: Skin and Mucous Membranes
  Fifth character (Approach) is value X: External
  Sixth character (Substance) is value 2: Anti-infective
  Seventh character (Qualifier) has 2 choices.
    First choice is value 8: Oxazolidinones
    Second choice is value 9: Other Anti-infective

No change: Third panel of table 3 E 0
  Fourth character (Body System / Region) is value 0: Skin and Mucous Membranes
  Fifth character (Approach) is value X: External
  Sixth character (Substance) has 7 choices.
    First choice is value 3: Anti-inflammatory
    Second choice is value 4: Serum, Toxoid and Vaccine
    Third choice is value B: Anesthetic Agent
    Fourth choice is value K: Other Diagnostic Substance
    Fifth choice is value M: Pigment
    Sixth choice is value N: Analgesics, Hypnotics, Sedatives
    Seventh choice is value T: Destructive Agent
  Seventh character (Qualifier) is value Z: No Qualifier

FY2027: Fourth panel of table 3 E 0
  Fourth character (Body System / Region) is value 0: Skin and Mucous Membranes
  Fifth character (Approach) is value X: External
  Sixth character (Substance) is value G: Other Therapeutic Substance
  Seventh character (Qualifier) has 2 choices.
    First choice is value C: Other Substance
    Second choice is value F: Other Enzymatic/Chemical Agent

No change: Fifth panel of table 3 E 0
  Fourth character (Body System / Region) is value 1: Subcutaneous Tissue
  Fifth character (Approach) is value 0: Open
  Sixth character (Substance) is value 2: Anti-infective
  Seventh character (Qualifier) is value A: Anti-Infective Envelope

No change: Sixth panel of table 3 E 0
  Fourth character (Body System / Region) is value 1: Subcutaneous Tissue
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) is value 0: Antineoplastic
  Seventh character (Qualifier) has 2 choices.
    First choice is value 5: Other Antineoplastic
    Second choice is value M: Monoclonal Antibody

No change: Seventh panel of table 3 E 0
  Fourth character (Body System / Region) is value 1: Subcutaneous Tissue
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) is value 2: Anti-infective
  Seventh character (Qualifier) has 3 choices.
    First choice is value 8: Oxazolidinones
    Second choice is value 9: Other Anti-infective
    Third choice is value A: Anti-Infective Envelope

No change: Eighth panel of table 3 E 0
  Fourth character (Body System / Region) is value 1: Subcutaneous Tissue
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) has 8 choices.
    First choice is value 3: Anti-inflammatory
    Second choice is value 6: Nutritional Substance
    Third choice is value 7: Electrolytic and Water Balance Substance
    Fourth choice is value B: Anesthetic Agent
    Fifth choice is value H: Radioactive Substance
    Sixth choice is value K: Other Diagnostic Substance
    Seventh choice is value N: Analgesics, Hypnotics, Sedatives
    Eighth choice is value T: Destructive Agent
  Seventh character (Qualifier) is value Z: No Qualifier

No change: Ninth panel of table 3 E 0
  Fourth character (Body System / Region) is value 1: Subcutaneous Tissue
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) is value 4: Serum, Toxoid and Vaccine
  Seventh character (Qualifier) has 2 choices.
    First choice is value 0: Influenza Vaccine
    Second choice is value Z: No Qualifier

No change: Tenth panel of table 3 E 0
  Fourth character (Body System / Region) is value 1: Subcutaneous Tissue
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) is value G: Other Therapeutic Substance
  Seventh character (Qualifier) is value C: Other Substance

No change: Eleventh panel of table 3 E 0
  Fourth character (Body System / Region) is value 1: Subcutaneous Tissue
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) is value V: Hormone
  Seventh character (Qualifier) has 2 choices.
    First choice is value G: Insulin
    Second choice is value J: Other Hormone

FY2027: Twelfth panel of table 3 E 0
  Fourth character (Body System / Region) is value 1: Subcutaneous Tissue
  Fifth character (Approach) is value X: External
  Sixth character (Substance) is value G: Other Therapeutic Substance
  Seventh character (Qualifier) is value F: Other Enzymatic/Chemical Agent

No change: Thirteenth panel of table 3 E 0
  Fourth character (Body System / Region) is value 2: Muscle
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) is value 0: Antineoplastic
  Seventh character (Qualifier) has 2 choices.
    First choice is value 5: Other Antineoplastic
    Second choice is value M: Monoclonal Antibody

No change: Fourteenth panel of table 3 E 0
  Fourth character (Body System / Region) is value 2: Muscle
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) is value 2: Anti-infective
  Seventh character (Qualifier) has 2 choices.
    First choice is value 8: Oxazolidinones
    Second choice is value 9: Other Anti-infective

No change: Fifteenth panel of table 3 E 0
  Fourth character (Body System / Region) is value 2: Muscle
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) has 8 choices.
    First choice is value 3: Anti-inflammatory
    Second choice is value 6: Nutritional Substance
    Third choice is value 7: Electrolytic and Water Balance Substance
    Fourth choice is value B: Anesthetic Agent
    Fifth choice is value H: Radioactive Substance
    Sixth choice is value K: Other Diagnostic Substance
    Seventh choice is value N: Analgesics, Hypnotics, Sedatives
    Eighth choice is value T: Destructive Agent
  Seventh character (Qualifier) is value Z: No Qualifier

No change: Sixteenth panel of table 3 E 0
  Fourth character (Body System / Region) is value 2: Muscle
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) is value 4: Serum, Toxoid and Vaccine
  Seventh character (Qualifier) has 2 choices.
    First choice is value 0: Influenza Vaccine
    Second choice is value Z: No Qualifier

No change: Seventeenth panel of table 3 E 0
  Fourth character (Body System / Region) is value 2: Muscle
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) is value G: Other Therapeutic Substance
  Seventh character (Qualifier) is value C: Other Substance

No change: Eighteenth panel of table 3 E 0
  Fourth character (Body System / Region) is value 3: Peripheral Vein
  Fifth character (Approach) is value 0: Open
  Sixth character (Substance) is value 0: Antineoplastic
  Seventh character (Qualifier) has 5 choices.
    First choice is value 2: High-dose Interleukin-2
    Second choice is value 3: Low-dose Interleukin-2
    Third choice is value 5: Other Antineoplastic
    Fourth choice is value M: Monoclonal Antibody
    Fifth choice is value P: Clofarabine

No change: Nineteenth panel of table 3 E 0
  Fourth character (Body System / Region) is value 3: Peripheral Vein
  Fifth character (Approach) is value 0: Open
  Sixth character (Substance) is value 1: Thrombolytic
  Seventh character (Qualifier) has 2 choices.
    First choice is value 6: Recombinant Human-activated Protein C
    Second choice is value 7: Other Thrombolytic

No change: Twentieth panel of table 3 E 0
  Fourth character (Body System / Region) is value 3: Peripheral Vein
  Fifth character (Approach) is value 0: Open
  Sixth character (Substance) is value 2: Anti-infective
  Seventh character (Qualifier) has 2 choices.
    First choice is value 8: Oxazolidinones
    Second choice is value 9: Other Anti-infective

No change: Twenty-first panel of table 3 E 0
  Fourth character (Body System / Region) is value 3: Peripheral Vein
  Fifth character (Approach) is value 0: Open
  Sixth character (Substance) has 12 choices.
    First choice is value 3: Anti-inflammatory
    Second choice is value 4: Serum, Toxoid and Vaccine
    Third choice is value 6: Nutritional Substance
    Fourth choice is value 7: Electrolytic and Water Balance Substance
    Fifth choice is value F: Intracirculatory Anesthetic
    Sixth choice is value H: Radioactive Substance
    Seventh choice is value K: Other Diagnostic Substance
    Eighth choice is value N: Analgesics, Hypnotics, Sedatives
    Ninth choice is value P: Platelet Inhibitor
    Tenth choice is value R: Antiarrhythmic
    Eleventh choice is value T: Destructive Agent
    Twelfth choice is value X: Vasopressor
  Seventh character (Qualifier) is value Z: No Qualifier

No change: Twenty-second panel of table 3 E 0
  Fourth character (Body System / Region) is value 3: Peripheral Vein
  Fifth character (Approach) is value 0: Open
  Sixth character (Substance) is value G: Other Therapeutic Substance
  Seventh character (Qualifier) has 2 choices.
    First choice is value C: Other Substance
    Second choice is value N: Blood Brain Barrier Disruption

No change: Twenty-third panel of table 3 E 0
  Fourth character (Body System / Region) is value 3: Peripheral Vein
  Fifth character (Approach) is value 0: Open
  Sixth character (Substance) is value U: Pancreatic Islet Cells
  Seventh character (Qualifier) has 2 choices.
    First choice is value 0: Autologous
    Second choice is value 1: Nonautologous

No change: Twenty-fourth panel of table 3 E 0
  Fourth character (Body System / Region) is value 3: Peripheral Vein
  Fifth character (Approach) is value 0: Open
  Sixth character (Substance) is value V: Hormone
  Seventh character (Qualifier) has 3 choices.
    First choice is value G: Insulin
    Second choice is value H: Human B-type Natriuretic Peptide
    Third choice is value J: Other Hormone

No change: Twenty-fifth panel of table 3 E 0
  Fourth character (Body System / Region) is value 3: Peripheral Vein
  Fifth character (Approach) is value 0: Open
  Sixth character (Substance) is value W: Immunotherapeutic
  Seventh character (Qualifier) has 2 choices.
    First choice is value K: Immunostimulator
    Second choice is value L: Immunosuppressive

No change: Twenty-sixth panel of table 3 E 0
  Fourth character (Body System / Region) is value 3: Peripheral Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) is value 0: Antineoplastic
  Seventh character (Qualifier) has 5 choices.
    First choice is value 2: High-dose Interleukin-2
    Second choice is value 3: Low-dose Interleukin-2
    Third choice is value 5: Other Antineoplastic
    Fourth choice is value M: Monoclonal Antibody
    Fifth choice is value P: Clofarabine

No change: Twenty-seventh panel of table 3 E 0
  Fourth character (Body System / Region) is value 3: Peripheral Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) is value 1: Thrombolytic
  Seventh character (Qualifier) has 2 choices.
    First choice is value 6: Recombinant Human-activated Protein C
    Second choice is value 7: Other Thrombolytic

No change: Twenty-eighth panel of table 3 E 0
  Fourth character (Body System / Region) is value 3: Peripheral Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) is value 2: Anti-infective
  Seventh character (Qualifier) has 2 choices.
    First choice is value 8: Oxazolidinones
    Second choice is value 9: Other Anti-infective

No change: Twenty-ninth panel of table 3 E 0
  Fourth character (Body System / Region) is value 3: Peripheral Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) has 13 choices.
    First choice is value 3: Anti-inflammatory
    Second choice is value 4: Serum, Toxoid and Vaccine
    Third choice is value 6: Nutritional Substance
    Fourth choice is value 7: Electrolytic and Water Balance Substance
    Fifth choice is value A: Stem Cells, Embryonic
    Sixth choice is value F: Intracirculatory Anesthetic
    Seventh choice is value H: Radioactive Substance
    Eighth choice is value K: Other Diagnostic Substance
    Ninth choice is value N: Analgesics, Hypnotics, Sedatives
    Tenth choice is value P: Platelet Inhibitor
    Eleventh choice is value R: Antiarrhythmic
    Twelfth choice is value T: Destructive Agent
    Thirteenth choice is value X: Vasopressor
  Seventh character (Qualifier) is value Z: No Qualifier

No change: Thirtieth panel of table 3 E 0
  Fourth character (Body System / Region) is value 3: Peripheral Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) is value G: Other Therapeutic Substance
  Seventh character (Qualifier) has 4 choices.
    First choice is value C: Other Substance
    Second choice is value N: Blood Brain Barrier Disruption
    Third choice is value Q: Glucarpidase
    Fourth choice is value R: Other Therapeutic Monoclonal Antibody

No change: Thirty-first panel of table 3 E 0
  Fourth character (Body System / Region) is value 3: Peripheral Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) is value U: Pancreatic Islet Cells
  Seventh character (Qualifier) has 2 choices.
    First choice is value 0: Autologous
    Second choice is value 1: Nonautologous

No change: Thirty-second panel of table 3 E 0
  Fourth character (Body System / Region) is value 3: Peripheral Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) is value V: Hormone
  Seventh character (Qualifier) has 3 choices.
    First choice is value G: Insulin
    Second choice is value H: Human B-type Natriuretic Peptide
    Third choice is value J: Other Hormone

No change: Thirty-third panel of table 3 E 0
  Fourth character (Body System / Region) is value 3: Peripheral Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) is value W: Immunotherapeutic
  Seventh character (Qualifier) has 2 choices.
    First choice is value K: Immunostimulator
    Second choice is value L: Immunosuppressive

No change: Thirty-fourth panel of table 3 E 0
  Fourth character (Body System / Region) is value 4: Central Vein
  Fifth character (Approach) is value 0: Open
  Sixth character (Substance) is value 0: Antineoplastic
  Seventh character (Qualifier) has 5 choices.
    First choice is value 2: High-dose Interleukin-2
    Second choice is value 3: Low-dose Interleukin-2
    Third choice is value 5: Other Antineoplastic
    Fourth choice is value M: Monoclonal Antibody
    Fifth choice is value P: Clofarabine

No change: Thirty-fifth panel of table 3 E 0
  Fourth character (Body System / Region) is value 4: Central Vein
  Fifth character (Approach) is value 0: Open
  Sixth character (Substance) is value 1: Thrombolytic
  Seventh character (Qualifier) has 2 choices.
    First choice is value 6: Recombinant Human-activated Protein C
    Second choice is value 7: Other Thrombolytic

No change: Thirty-sixth panel of table 3 E 0
  Fourth character (Body System / Region) is value 4: Central Vein
  Fifth character (Approach) is value 0: Open
  Sixth character (Substance) is value 2: Anti-infective
  Seventh character (Qualifier) has 2 choices.
    First choice is value 8: Oxazolidinones
    Second choice is value 9: Other Anti-infective

No change: Thirty-seventh panel of table 3 E 0
  Fourth character (Body System / Region) is value 4: Central Vein
  Fifth character (Approach) is value 0: Open
  Sixth character (Substance) has 12 choices.
    First choice is value 3: Anti-inflammatory
    Second choice is value 4: Serum, Toxoid and Vaccine
    Third choice is value 6: Nutritional Substance
    Fourth choice is value 7: Electrolytic and Water Balance Substance
    Fifth choice is value F: Intracirculatory Anesthetic
    Sixth choice is value H: Radioactive Substance
    Seventh choice is value K: Other Diagnostic Substance
    Eighth choice is value N: Analgesics, Hypnotics, Sedatives
    Ninth choice is value P: Platelet Inhibitor
    Tenth choice is value R: Antiarrhythmic
    Eleventh choice is value T: Destructive Agent
    Twelfth choice is value X: Vasopressor
  Seventh character (Qualifier) is value Z: No Qualifier

No change: Thirty-eighth panel of table 3 E 0
  Fourth character (Body System / Region) is value 4: Central Vein
  Fifth character (Approach) is value 0: Open
  Sixth character (Substance) is value G: Other Therapeutic Substance
  Seventh character (Qualifier) has 2 choices.
    First choice is value C: Other Substance
    Second choice is value N: Blood Brain Barrier Disruption

No change: Thirty-ninth panel of table 3 E 0
  Fourth character (Body System / Region) is value 4: Central Vein
  Fifth character (Approach) is value 0: Open
  Sixth character (Substance) is value V: Hormone
  Seventh character (Qualifier) has 3 choices.
    First choice is value G: Insulin
    Second choice is value H: Human B-type Natriuretic Peptide
    Third choice is value J: Other Hormone

No change: Fortieth panel of table 3 E 0
  Fourth character (Body System / Region) is value 4: Central Vein
  Fifth character (Approach) is value 0: Open
  Sixth character (Substance) is value W: Immunotherapeutic
  Seventh character (Qualifier) has 2 choices.
    First choice is value K: Immunostimulator
    Second choice is value L: Immunosuppressive

No change: Forty-first panel of table 3 E 0
  Fourth character (Body System / Region) is value 4: Central Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) is value 0: Antineoplastic
  Seventh character (Qualifier) has 5 choices.
    First choice is value 2: High-dose Interleukin-2
    Second choice is value 3: Low-dose Interleukin-2
    Third choice is value 5: Other Antineoplastic
    Fourth choice is value M: Monoclonal Antibody
    Fifth choice is value P: Clofarabine

No change: Forty-second panel of table 3 E 0
  Fourth character (Body System / Region) is value 4: Central Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) is value 1: Thrombolytic
  Seventh character (Qualifier) has 2 choices.
    First choice is value 6: Recombinant Human-activated Protein C
    Second choice is value 7: Other Thrombolytic

No change: Forty-third panel of table 3 E 0
  Fourth character (Body System / Region) is value 4: Central Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) is value 2: Anti-infective
  Seventh character (Qualifier) has 2 choices.
    First choice is value 8: Oxazolidinones
    Second choice is value 9: Other Anti-infective

No change: Forty-fourth panel of table 3 E 0
  Fourth character (Body System / Region) is value 4: Central Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) has 13 choices.
    First choice is value 3: Anti-inflammatory
    Second choice is value 4: Serum, Toxoid and Vaccine
    Third choice is value 6: Nutritional Substance
    Fourth choice is value 7: Electrolytic and Water Balance Substance
    Fifth choice is value A: Stem Cells, Embryonic
    Sixth choice is value F: Intracirculatory Anesthetic
    Seventh choice is value H: Radioactive Substance
    Eighth choice is value K: Other Diagnostic Substance
    Ninth choice is value N: Analgesics, Hypnotics, Sedatives
    Tenth choice is value P: Platelet Inhibitor
    Eleventh choice is value R: Antiarrhythmic
    Twelfth choice is value T: Destructive Agent
    Thirteenth choice is value X: Vasopressor
  Seventh character (Qualifier) is value Z: No Qualifier

No change: Forty-fifth panel of table 3 E 0
  Fourth character (Body System / Region) is value 4: Central Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) is value G: Other Therapeutic Substance
  Seventh character (Qualifier) has 4 choices.
    First choice is value C: Other Substance
    Second choice is value N: Blood Brain Barrier Disruption
    Third choice is value Q: Glucarpidase
    Fourth choice is value R: Other Therapeutic Monoclonal Antibody

No change: Forty-sixth panel of table 3 E 0
  Fourth character (Body System / Region) is value 4: Central Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) is value V: Hormone
  Seventh character (Qualifier) has 3 choices.
    First choice is value G: Insulin
    Second choice is value H: Human B-type Natriuretic Peptide
    Third choice is value J: Other Hormone

No change: Forty-seventh panel of table 3 E 0
  Fourth character (Body System / Region) is value 4: Central Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) is value W: Immunotherapeutic
  Seventh character (Qualifier) has 2 choices.
    First choice is value K: Immunostimulator
    Second choice is value L: Immunosuppressive

No change: Forty-eighth panel of table 3 E 0
  Fourth character (Body System / Region) has 2 choices.
    First choice is value 5: Peripheral Artery
    Second choice is value 6: Central Artery
  Fifth character (Approach) has 2 choices.
    First choice is value 0: Open
    Second choice is value 3: Percutaneous
  Sixth character (Substance) is value 0: Antineoplastic
  Seventh character (Qualifier) has 5 choices.
    First choice is value 2: High-dose Interleukin-2
    Second choice is value 3: Low-dose Interleukin-2
    Third choice is value 5: Other Antineoplastic
    Fourth choice is value M: Monoclonal Antibody
    Fifth choice is value P: Clofarabine

No change: Forty-ninth panel of table 3 E 0
  Fourth character (Body System / Region) has 2 choices.
    First choice is value 5: Peripheral Artery
    Second choice is value 6: Central Artery
  Fifth character (Approach) has 2 choices.
    First choice is value 0: Open
    Second choice is value 3: Percutaneous
  Sixth character (Substance) is value 1: Thrombolytic
  Seventh character (Qualifier) has 2 choices.
    First choice is value 6: Recombinant Human-activated Protein C
    Second choice is value 7: Other Thrombolytic

No change: Fiftieth panel of table 3 E 0
  Fourth character (Body System / Region) has 2 choices.
    First choice is value 5: Peripheral Artery
    Second choice is value 6: Central Artery
  Fifth character (Approach) has 2 choices.
    First choice is value 0: Open
    Second choice is value 3: Percutaneous
  Sixth character (Substance) is value 2: Anti-infective
  Seventh character (Qualifier) has 2 choices.
    First choice is value 8: Oxazolidinones
    Second choice is value 9: Other Anti-infective

No change: Fifty-first panel of table 3 E 0
  Fourth character (Body System / Region) has 2 choices.
    First choice is value 5: Peripheral Artery
    Second choice is value 6: Central Artery
  Fifth character (Approach) has 2 choices.
    First choice is value 0: Open
    Second choice is value 3: Percutaneous
  Sixth character (Substance) has 12 choices.
    First choice is value 3: Anti-inflammatory
    Second choice is value 4: Serum, Toxoid and Vaccine
    Third choice is value 6: Nutritional Substance
    Fourth choice is value 7: Electrolytic and Water Balance Substance
    Fifth choice is value F: Intracirculatory Anesthetic
    Sixth choice is value H: Radioactive Substance
    Seventh choice is value K: Other Diagnostic Substance
    Eighth choice is value N: Analgesics, Hypnotics, Sedatives
    Ninth choice is value P: Platelet Inhibitor
    Tenth choice is value R: Antiarrhythmic
    Eleventh choice is value T: Destructive Agent
    Twelfth choice is value X: Vasopressor
  Seventh character (Qualifier) is value Z: No Qualifier

No change: Fifty-second panel of table 3 E 0
  Fourth character (Body System / Region) has 2 choices.
    First choice is value 5: Peripheral Artery
    Second choice is value 6: Central Artery
  Fifth character (Approach) has 2 choices.
    First choice is value 0: Open
    Second choice is value 3: Percutaneous
  Sixth character (Substance) is value G: Other Therapeutic Substance
  Seventh character (Qualifier) has 2 choices.
    First choice is value C: Other Substance
    Second choice is value N: Blood Brain Barrier Disruption

No change: Fifty-third panel of table 3 E 0
  Fourth character (Body System / Region) has 2 choices.
    First choice is value 5: Peripheral Artery
    Second choice is value 6: Central Artery
  Fifth character (Approach) has 2 choices.
    First choice is value 0: Open
    Second choice is value 3: Percutaneous
  Sixth character (Substance) is value V: Hormone
  Seventh character (Qualifier) has 3 choices.
    First choice is value G: Insulin
    Second choice is value H: Human B-type Natriuretic Peptide
    Third choice is value J: Other Hormone

No change: Fifty-fourth panel of table 3 E 0
  Fourth character (Body System / Region) has 2 choices.
    First choice is value 5: Peripheral Artery
    Second choice is value 6: Central Artery
  Fifth character (Approach) has 2 choices.
    First choice is value 0: Open
    Second choice is value 3: Percutaneous
  Sixth character (Substance) is value W: Immunotherapeutic
  Seventh character (Qualifier) has 2 choices.
    First choice is value K: Immunostimulator
    Second choice is value L: Immunosuppressive

No change: Fifty-fifth panel of table 3 E 0
  Fourth character (Body System / Region) has 2 choices.
    First choice is value 7: Coronary Artery
    Second choice is value 8: Heart
  Fifth character (Approach) has 2 choices.
    First choice is value 0: Open
    Second choice is value 3: Percutaneous
  Sixth character (Substance) is value 1: Thrombolytic
  Seventh character (Qualifier) has 2 choices.
    First choice is value 6: Recombinant Human-activated Protein C
    Second choice is value 7: Other Thrombolytic

No change: Fifty-sixth panel of table 3 E 0
  Fourth character (Body System / Region) has 2 choices.
    First choice is value 7: Coronary Artery
    Second choice is value 8: Heart
  Fifth character (Approach) has 2 choices.
    First choice is value 0: Open
    Second choice is value 3: Percutaneous
  Sixth character (Substance) is value G: Other Therapeutic Substance
  Seventh character (Qualifier) is value C: Other Substance

No change: Fifty-seventh panel of table 3 E 0
  Fourth character (Body System / Region) has 2 choices.
    First choice is value 7: Coronary Artery
    Second choice is value 8: Heart
  Fifth character (Approach) has 2 choices.
    First choice is value 0: Open
    Second choice is value 3: Percutaneous
  Sixth character (Substance) has 2 choices.
    First choice is value K: Other Diagnostic Substance
    Second choice is value P: Platelet Inhibitor
  Seventh character (Qualifier) is value Z: No Qualifier

No change: Fifty-eighth panel of table 3 E 0
  Fourth character (Body System / Region) has 2 choices.
    First choice is value 7: Coronary Artery
    Second choice is value 8: Heart
  Fifth character (Approach) is value 4: Percutaneous Endoscopic
  Sixth character (Substance) is value G: Other Therapeutic Substance
  Seventh character (Qualifier) is value C: Other Substance

No change: Fifty-ninth panel of table 3 E 0
  Fourth character (Body System / Region) is value 9: Nose
  Fifth character (Approach) has 3 choices.
    First choice is value 3: Percutaneous
    Second choice is value 7: Via Natural or Artificial Opening
    Third choice is value X: External
  Sixth character (Substance) is value 0: Antineoplastic
  Seventh character (Qualifier) has 2 choices.
    First choice is value 5: Other Antineoplastic
    Second choice is value M: Monoclonal Antibody

No change: Sixtieth panel of table 3 E 0
  Fourth character (Body System / Region) is value 9: Nose
  Fifth character (Approach) has 3 choices.
    First choice is value 3: Percutaneous
    Second choice is value 7: Via Natural or Artificial Opening
    Third choice is value X: External
  Sixth character (Substance) is value 2: Anti-infective
  Seventh character (Qualifier) has 2 choices.
    First choice is value 8: Oxazolidinones
    Second choice is value 9: Other Anti-infective

No change: Sixty-first panel of table 3 E 0
  Fourth character (Body System / Region) is value 9: Nose
  Fifth character (Approach) has 3 choices.
    First choice is value 3: Percutaneous
    Second choice is value 7: Via Natural or Artificial Opening
    Third choice is value X: External
  Sixth character (Substance) has 7 choices.
    First choice is value 3: Anti-inflammatory
    Second choice is value 4: Serum, Toxoid and Vaccine
    Third choice is value B: Anesthetic Agent
    Fourth choice is value H: Radioactive Substance
    Fifth choice is value K: Other Diagnostic Substance
    Sixth choice is value N: Analgesics, Hypnotics, Sedatives
    Seventh choice is value T: Destructive Agent
  Seventh character (Qualifier) is value Z: No Qualifier

No change: Sixty-second panel of table 3 E 0
  Fourth character (Body System / Region) is value 9: Nose
  Fifth character (Approach) has 3 choices.
    First choice is value 3: Percutaneous
    Second choice is value 7: Via Natural or Artificial Opening
    Third choice is value X: External
  Sixth character (Substance) is value G: Other Therapeutic Substance
  Seventh character (Qualifier) is value C: Other Substance

No change: Sixty-third panel of table 3 E 0
  Fourth character (Body System / Region) is value A: Bone Marrow
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) is value 0: Antineoplastic
  Seventh character (Qualifier) has 2 choices.
    First choice is value 5: Other Antineoplastic
    Second choice is value M: Monoclonal Antibody

No change: Sixty-fourth panel of table 3 E 0
  Fourth character (Body System / Region) is value A: Bone Marrow
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) is value G: Other Therapeutic Substance
  Seventh character (Qualifier) is value C: Other Substance

No change: Sixty-fifth panel of table 3 E 0
  Fourth character (Body System / Region) is value B: Ear
  Fifth character (Approach) has 3 choices.
    First choice is value 3: Percutaneous
    Second choice is value 7: Via Natural or Artificial Opening
    Third choice is value X: External
  Sixth character (Substance) is value 0: Antineoplastic
  Seventh character (Qualifier) has 3 choices.
    First choice is value 4: Liquid Brachytherapy Radioisotope
    Second choice is value 5: Other Antineoplastic
    Third choice is value M: Monoclonal Antibody

No change: Sixty-sixth panel of table 3 E 0
  Fourth character (Body System / Region) is value B: Ear
  Fifth character (Approach) has 3 choices.
    First choice is value 3: Percutaneous
    Second choice is value 7: Via Natural or Artificial Opening
    Third choice is value X: External
  Sixth character (Substance) is value 2: Anti-infective
  Seventh character (Qualifier) has 2 choices.
    First choice is value 8: Oxazolidinones
    Second choice is value 9: Other Anti-infective

No change: Sixty-seventh panel of table 3 E 0
  Fourth character (Body System / Region) is value B: Ear
  Fifth character (Approach) has 3 choices.
    First choice is value 3: Percutaneous
    Second choice is value 7: Via Natural or Artificial Opening
    Third choice is value X: External
  Sixth character (Substance) has 6 choices.
    First choice is value 3: Anti-inflammatory
    Second choice is value B: Anesthetic Agent
    Third choice is value H: Radioactive Substance
    Fourth choice is value K: Other Diagnostic Substance
    Fifth choice is value N: Analgesics, Hypnotics, Sedatives
    Sixth choice is value T: Destructive Agent
  Seventh character (Qualifier) is value Z: No Qualifier

No change: Sixty-eighth panel of table 3 E 0
  Fourth character (Body System / Region) is value B: Ear
  Fifth character (Approach) has 3 choices.
    First choice is value 3: Percutaneous
    Second choice is value 7: Via Natural or Artificial Opening
    Third choice is value X: External
  Sixth character (Substance) is value G: Other Therapeutic Substance
  Seventh character (Qualifier) is value C: Other Substance

No change: Sixty-ninth panel of table 3 E 0
  Fourth character (Body System / Region) is value C: Eye
  Fifth character (Approach) has 3 choices.
    First choice is value 3: Percutaneous
    Second choice is value 7: Via Natural or Artificial Opening
    Third choice is value X: External
  Sixth character (Substance) is value 0: Antineoplastic
  Seventh character (Qualifier) has 3 choices.
    First choice is value 4: Liquid Brachytherapy Radioisotope
    Second choice is value 5: Other Antineoplastic
    Third choice is value M: Monoclonal Antibody

No change: Seventieth panel of table 3 E 0
  Fourth character (Body System / Region) is value C: Eye
  Fifth character (Approach) has 3 choices.
    First choice is value 3: Percutaneous
    Second choice is value 7: Via Natural or Artificial Opening
    Third choice is value X: External
  Sixth character (Substance) is value 2: Anti-infective
  Seventh character (Qualifier) has 2 choices.
    First choice is value 8: Oxazolidinones
    Second choice is value 9: Other Anti-infective

No change: Seventy-first panel of table 3 E 0
  Fourth character (Body System / Region) is value C: Eye
  Fifth character (Approach) has 3 choices.
    First choice is value 3: Percutaneous
    Second choice is value 7: Via Natural or Artificial Opening
    Third choice is value X: External
  Sixth character (Substance) has 7 choices.
    First choice is value 3: Anti-inflammatory
    Second choice is value B: Anesthetic Agent
    Third choice is value H: Radioactive Substance
    Fourth choice is value K: Other Diagnostic Substance
    Fifth choice is value M: Pigment
    Sixth choice is value N: Analgesics, Hypnotics, Sedatives
    Seventh choice is value T: Destructive Agent
  Seventh character (Qualifier) is value Z: No Qualifier

No change: Seventy-second panel of table 3 E 0
  Fourth character (Body System / Region) is value C: Eye
  Fifth character (Approach) has 3 choices.
    First choice is value 3: Percutaneous
    Second choice is value 7: Via Natural or Artificial Opening
    Third choice is value X: External
  Sixth character (Substance) is value G: Other Therapeutic Substance
  Seventh character (Qualifier) is value C: Other Substance

No change: Seventy-third panel of table 3 E 0
  Fourth character (Body System / Region) is value C: Eye
  Fifth character (Approach) has 3 choices.
    First choice is value 3: Percutaneous
    Second choice is value 7: Via Natural or Artificial Opening
    Third choice is value X: External
  Sixth character (Substance) is value S: Gas
  Seventh character (Qualifier) is value F: Other Gas

No change: Seventy-fourth panel of table 3 E 0
  Fourth character (Body System / Region) is value D: Mouth and Pharynx
  Fifth character (Approach) has 3 choices.
    First choice is value 3: Percutaneous
    Second choice is value 7: Via Natural or Artificial Opening
    Third choice is value X: External
  Sixth character (Substance) is value 0: Antineoplastic
  Seventh character (Qualifier) has 3 choices.
    First choice is value 4: Liquid Brachytherapy Radioisotope
    Second choice is value 5: Other Antineoplastic
    Third choice is value M: Monoclonal Antibody

No change: Seventy-fifth panel of table 3 E 0
  Fourth character (Body System / Region) is value D: Mouth and Pharynx
  Fifth character (Approach) has 3 choices.
    First choice is value 3: Percutaneous
    Second choice is value 7: Via Natural or Artificial Opening
    Third choice is value X: External
  Sixth character (Substance) is value 2: Anti-infective
  Seventh character (Qualifier) has 2 choices.
    First choice is value 8: Oxazolidinones
    Second choice is value 9: Other Anti-infective

No change: Seventy-sixth panel of table 3 E 0
  Fourth character (Body System / Region) is value D: Mouth and Pharynx
  Fifth character (Approach) has 3 choices.
    First choice is value 3: Percutaneous
    Second choice is value 7: Via Natural or Artificial Opening
    Third choice is value X: External
  Sixth character (Substance) has 10 choices.
    First choice is value 3: Anti-inflammatory
    Second choice is value 4: Serum, Toxoid and Vaccine
    Third choice is value 6: Nutritional Substance
    Fourth choice is value 7: Electrolytic and Water Balance Substance
    Fifth choice is value B: Anesthetic Agent
    Sixth choice is value H: Radioactive Substance
    Seventh choice is value K: Other Diagnostic Substance
    Eighth choice is value N: Analgesics, Hypnotics, Sedatives
    Ninth choice is value R: Antiarrhythmic
    Tenth choice is value T: Destructive Agent
  Seventh character (Qualifier) is value Z: No Qualifier

No change: Seventy-seventh panel of table 3 E 0
  Fourth character (Body System / Region) is value D: Mouth and Pharynx
  Fifth character (Approach) has 3 choices.
    First choice is value 3: Percutaneous
    Second choice is value 7: Via Natural or Artificial Opening
    Third choice is value X: External
  Sixth character (Substance) is value G: Other Therapeutic Substance
  Seventh character (Qualifier) is value C: Other Substance

No change: Seventy-eighth panel of table 3 E 0
  Fourth character (Body System / Region) has 5 choices.
    First choice is value E: Products of Conception
    Second choice is value G: Upper GI
    Third choice is value H: Lower GI
    Fourth choice is value K: Genitourinary Tract
    Fifth choice is value N: Male Reproductive
  Fifth character (Approach) has 3 choices.
    First choice is value 3: Percutaneous
    Second choice is value 7: Via Natural or Artificial Opening
    Third choice is value 8: Via Natural or Artificial Opening Endoscopic
  Sixth character (Substance) is value 0: Antineoplastic
  Seventh character (Qualifier) has 3 choices.
    First choice is value 4: Liquid Brachytherapy Radioisotope
    Second choice is value 5: Other Antineoplastic
    Third choice is value M: Monoclonal Antibody

No change: Seventy-ninth panel of table 3 E 0
  Fourth character (Body System / Region) has 5 choices.
    First choice is value E: Products of Conception
    Second choice is value G: Upper GI
    Third choice is value H: Lower GI
    Fourth choice is value K: Genitourinary Tract
    Fifth choice is value N: Male Reproductive
  Fifth character (Approach) has 3 choices.
    First choice is value 3: Percutaneous
    Second choice is value 7: Via Natural or Artificial Opening
    Third choice is value 8: Via Natural or Artificial Opening Endoscopic
  Sixth character (Substance) is value 2: Anti-infective
  Seventh character (Qualifier) has 2 choices.
    First choice is value 8: Oxazolidinones
    Second choice is value 9: Other Anti-infective

No change: Eightieth panel of table 3 E 0
  Fourth character (Body System / Region) has 5 choices.
    First choice is value E: Products of Conception
    Second choice is value G: Upper GI
    Third choice is value H: Lower GI
    Fourth choice is value K: Genitourinary Tract
    Fifth choice is value N: Male Reproductive
  Fifth character (Approach) has 3 choices.
    First choice is value 3: Percutaneous
    Second choice is value 7: Via Natural or Artificial Opening
    Third choice is value 8: Via Natural or Artificial Opening Endoscopic
  Sixth character (Substance) has 8 choices.
    First choice is value 3: Anti-inflammatory
    Second choice is value 6: Nutritional Substance
    Third choice is value 7: Electrolytic and Water Balance Substance
    Fourth choice is value B: Anesthetic Agent
    Fifth choice is value H: Radioactive Substance
    Sixth choice is value K: Other Diagnostic Substance
    Seventh choice is value N: Analgesics, Hypnotics, Sedatives
    Eighth choice is value T: Destructive Agent
  Seventh character (Qualifier) is value Z: No Qualifier

No change: Eighty-first panel of table 3 E 0
  Fourth character (Body System / Region) has 5 choices.
    First choice is value E: Products of Conception
    Second choice is value G: Upper GI
    Third choice is value H: Lower GI
    Fourth choice is value K: Genitourinary Tract
    Fifth choice is value N: Male Reproductive
  Fifth character (Approach) has 3 choices.
    First choice is value 3: Percutaneous
    Second choice is value 7: Via Natural or Artificial Opening
    Third choice is value 8: Via Natural or Artificial Opening Endoscopic
  Sixth character (Substance) is value G: Other Therapeutic Substance
  Seventh character (Qualifier) is value C: Other Substance

No change: Eighty-second panel of table 3 E 0
  Fourth character (Body System / Region) has 5 choices.
    First choice is value E: Products of Conception
    Second choice is value G: Upper GI
    Third choice is value H: Lower GI
    Fourth choice is value K: Genitourinary Tract
    Fifth choice is value N: Male Reproductive
  Fifth character (Approach) has 3 choices.
    First choice is value 3: Percutaneous
    Second choice is value 7: Via Natural or Artificial Opening
    Third choice is value 8: Via Natural or Artificial Opening Endoscopic
  Sixth character (Substance) is value S: Gas
  Seventh character (Qualifier) is value F: Other Gas

No change: Eighty-third panel of table 3 E 0
  Fourth character (Body System / Region) has 5 choices.
    First choice is value E: Products of Conception
    Second choice is value G: Upper GI
    Third choice is value H: Lower GI
    Fourth choice is value K: Genitourinary Tract
    Fifth choice is value N: Male Reproductive
  Fifth character (Approach) is value 4: Percutaneous Endoscopic
  Sixth character (Substance) is value G: Other Therapeutic Substance
  Seventh character (Qualifier) is value C: Other Substance

No change: Eighty-fourth panel of table 3 E 0
  Fourth character (Body System / Region) is value F: Respiratory Tract
  Fifth character (Approach) has 3 choices.
    First choice is value 3: Percutaneous
    Second choice is value 7: Via Natural or Artificial Opening
    Third choice is value 8: Via Natural or Artificial Opening Endoscopic
  Sixth character (Substance) is value 0: Antineoplastic
  Seventh character (Qualifier) has 3 choices.
    First choice is value 4: Liquid Brachytherapy Radioisotope
    Second choice is value 5: Other Antineoplastic
    Third choice is value M: Monoclonal Antibody

No change: Eighty-fifth panel of table 3 E 0
  Fourth character (Body System / Region) is value F: Respiratory Tract
  Fifth character (Approach) has 3 choices.
    First choice is value 3: Percutaneous
    Second choice is value 7: Via Natural or Artificial Opening
    Third choice is value 8: Via Natural or Artificial Opening Endoscopic
  Sixth character (Substance) is value 2: Anti-infective
  Seventh character (Qualifier) has 2 choices.
    First choice is value 8: Oxazolidinones
    Second choice is value 9: Other Anti-infective

No change: Eighty-sixth panel of table 3 E 0
  Fourth character (Body System / Region) is value F: Respiratory Tract
  Fifth character (Approach) has 3 choices.
    First choice is value 3: Percutaneous
    Second choice is value 7: Via Natural or Artificial Opening
    Third choice is value 8: Via Natural or Artificial Opening Endoscopic
  Sixth character (Substance) has 8 choices.
    First choice is value 3: Anti-inflammatory
    Second choice is value 6: Nutritional Substance
    Third choice is value 7: Electrolytic and Water Balance Substance
    Fourth choice is value B: Anesthetic Agent
    Fifth choice is value H: Radioactive Substance
    Sixth choice is value K: Other Diagnostic Substance
    Seventh choice is value N: Analgesics, Hypnotics, Sedatives
    Eighth choice is value T: Destructive Agent
  Seventh character (Qualifier) is value Z: No Qualifier

No change: Eighty-seventh panel of table 3 E 0
  Fourth character (Body System / Region) is value F: Respiratory Tract
  Fifth character (Approach) has 3 choices.
    First choice is value 3: Percutaneous
    Second choice is value 7: Via Natural or Artificial Opening
    Third choice is value 8: Via Natural or Artificial Opening Endoscopic
  Sixth character (Substance) is value G: Other Therapeutic Substance
  Seventh character (Qualifier) is value C: Other Substance

No change: Eighty-eighth panel of table 3 E 0
  Fourth character (Body System / Region) is value F: Respiratory Tract
  Fifth character (Approach) has 3 choices.
    First choice is value 3: Percutaneous
    Second choice is value 7: Via Natural or Artificial Opening
    Third choice is value 8: Via Natural or Artificial Opening Endoscopic
  Sixth character (Substance) is value S: Gas
  Seventh character (Qualifier) has 2 choices.
    First choice is value D: Nitric Oxide
    Second choice is value F: Other Gas

No change: Eighty-ninth panel of table 3 E 0
  Fourth character (Body System / Region) is value F: Respiratory Tract
  Fifth character (Approach) is value 4: Percutaneous Endoscopic
  Sixth character (Substance) is value G: Other Therapeutic Substance
  Seventh character (Qualifier) is value C: Other Substance

No change: Ninetieth panel of table 3 E 0
  Fourth character (Body System / Region) is value J: Biliary and Pancreatic Tract
  Fifth character (Approach) has 3 choices.
    First choice is value 3: Percutaneous
    Second choice is value 7: Via Natural or Artificial Opening
    Third choice is value 8: Via Natural or Artificial Opening Endoscopic
  Sixth character (Substance) is value 0: Antineoplastic
  Seventh character (Qualifier) has 3 choices.
    First choice is value 4: Liquid Brachytherapy Radioisotope
    Second choice is value 5: Other Antineoplastic
    Third choice is value M: Monoclonal Antibody

No change: Ninety-first panel of table 3 E 0
  Fourth character (Body System / Region) is value J: Biliary and Pancreatic Tract
  Fifth character (Approach) has 3 choices.
    First choice is value 3: Percutaneous
    Second choice is value 7: Via Natural or Artificial Opening
    Third choice is value 8: Via Natural or Artificial Opening Endoscopic
  Sixth character (Substance) is value 2: Anti-infective
  Seventh character (Qualifier) has 2 choices.
    First choice is value 8: Oxazolidinones
    Second choice is value 9: Other Anti-infective

No change: Ninety-second panel of table 3 E 0
  Fourth character (Body System / Region) is value J: Biliary and Pancreatic Tract
  Fifth character (Approach) has 3 choices.
    First choice is value 3: Percutaneous
    Second choice is value 7: Via Natural or Artificial Opening
    Third choice is value 8: Via Natural or Artificial Opening Endoscopic
  Sixth character (Substance) has 8 choices.
    First choice is value 3: Anti-inflammatory
    Second choice is value 6: Nutritional Substance
    Third choice is value 7: Electrolytic and Water Balance Substance
    Fourth choice is value B: Anesthetic Agent
    Fifth choice is value H: Radioactive Substance
    Sixth choice is value K: Other Diagnostic Substance
    Seventh choice is value N: Analgesics, Hypnotics, Sedatives
    Eighth choice is value T: Destructive Agent
  Seventh character (Qualifier) is value Z: No Qualifier

No change: Ninety-third panel of table 3 E 0
  Fourth character (Body System / Region) is value J: Biliary and Pancreatic Tract
  Fifth character (Approach) has 3 choices.
    First choice is value 3: Percutaneous
    Second choice is value 7: Via Natural or Artificial Opening
    Third choice is value 8: Via Natural or Artificial Opening Endoscopic
  Sixth character (Substance) is value G: Other Therapeutic Substance
  Seventh character (Qualifier) is value C: Other Substance

No change: Ninety-fourth panel of table 3 E 0
  Fourth character (Body System / Region) is value J: Biliary and Pancreatic Tract
  Fifth character (Approach) has 3 choices.
    First choice is value 3: Percutaneous
    Second choice is value 7: Via Natural or Artificial Opening
    Third choice is value 8: Via Natural or Artificial Opening Endoscopic
  Sixth character (Substance) is value S: Gas
  Seventh character (Qualifier) is value F: Other Gas

No change: Ninety-fifth panel of table 3 E 0
  Fourth character (Body System / Region) is value J: Biliary and Pancreatic Tract
  Fifth character (Approach) has 3 choices.
    First choice is value 3: Percutaneous
    Second choice is value 7: Via Natural or Artificial Opening
    Third choice is value 8: Via Natural or Artificial Opening Endoscopic
  Sixth character (Substance) is value U: Pancreatic Islet Cells
  Seventh character (Qualifier) has 2 choices.
    First choice is value 0: Autologous
    Second choice is value 1: Nonautologous

No change: Ninety-sixth panel of table 3 E 0
  Fourth character (Body System / Region) is value J: Biliary and Pancreatic Tract
  Fifth character (Approach) is value 4: Percutaneous Endoscopic
  Sixth character (Substance) is value G: Other Therapeutic Substance
  Seventh character (Qualifier) is value C: Other Substance

No change: Ninety-seventh panel of table 3 E 0
  Fourth character (Body System / Region) is value L: Pleural Cavity
  Fifth character (Approach) is value 0: Open
  Sixth character (Substance) is value 5: Adhesion Barrier
  Seventh character (Qualifier) is value Z: No Qualifier

No change: Ninety-eighth panel of table 3 E 0
  Fourth character (Body System / Region) is value L: Pleural Cavity
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) is value 0: Antineoplastic
  Seventh character (Qualifier) has 3 choices.
    First choice is value 4: Liquid Brachytherapy Radioisotope
    Second choice is value 5: Other Antineoplastic
    Third choice is value M: Monoclonal Antibody

No change: Ninety-ninth panel of table 3 E 0
  Fourth character (Body System / Region) is value L: Pleural Cavity
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) is value 1: Thrombolytic
  Seventh character (Qualifier) is value 7: Other Thrombolytic

No change: One hundredth panel of table 3 E 0
  Fourth character (Body System / Region) is value L: Pleural Cavity
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) is value 2: Anti-infective
  Seventh character (Qualifier) has 2 choices.
    First choice is value 8: Oxazolidinones
    Second choice is value 9: Other Anti-infective

No change: One hundred First panel of table 3 E 0
  Fourth character (Body System / Region) is value L: Pleural Cavity
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) has 9 choices.
    First choice is value 3: Anti-inflammatory
    Second choice is value 5: Adhesion Barrier
    Third choice is value 6: Nutritional Substance
    Fourth choice is value 7: Electrolytic and Water Balance Substance
    Fifth choice is value B: Anesthetic Agent
    Sixth choice is value H: Radioactive Substance
    Seventh choice is value K: Other Diagnostic Substance
    Eighth choice is value N: Analgesics, Hypnotics, Sedatives
    Ninth choice is value T: Destructive Agent
  Seventh character (Qualifier) is value Z: No Qualifier

No change: One hundred Second panel of table 3 E 0
  Fourth character (Body System / Region) is value L: Pleural Cavity
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) is value G: Other Therapeutic Substance
  Seventh character (Qualifier) is value C: Other Substance

No change: One hundred Third panel of table 3 E 0
  Fourth character (Body System / Region) is value L: Pleural Cavity
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) is value S: Gas
  Seventh character (Qualifier) is value F: Other Gas

No change: One hundred Fourth panel of table 3 E 0
  Fourth character (Body System / Region) is value L: Pleural Cavity
  Fifth character (Approach) is value 4: Percutaneous Endoscopic
  Sixth character (Substance) is value 5: Adhesion Barrier
  Seventh character (Qualifier) is value Z: No Qualifier

No change: One hundred Fifth panel of table 3 E 0
  Fourth character (Body System / Region) is value L: Pleural Cavity
  Fifth character (Approach) is value 4: Percutaneous Endoscopic
  Sixth character (Substance) is value G: Other Therapeutic Substance
  Seventh character (Qualifier) is value C: Other Substance

No change: One hundred Sixth panel of table 3 E 0
  Fourth character (Body System / Region) is value L: Pleural Cavity
  Fifth character (Approach) is value 7: Via Natural or Artificial Opening
  Sixth character (Substance) is value 0: Antineoplastic
  Seventh character (Qualifier) has 3 choices.
    First choice is value 4: Liquid Brachytherapy Radioisotope
    Second choice is value 5: Other Antineoplastic
    Third choice is value M: Monoclonal Antibody

No change: One hundred Seventh panel of table 3 E 0
  Fourth character (Body System / Region) is value L: Pleural Cavity
  Fifth character (Approach) is value 7: Via Natural or Artificial Opening
  Sixth character (Substance) is value S: Gas
  Seventh character (Qualifier) is value F: Other Gas

No change: One hundred Eighth panel of table 3 E 0
  Fourth character (Body System / Region) is value M: Peritoneal Cavity
  Fifth character (Approach) is value 0: Open
  Sixth character (Substance) is value 5: Adhesion Barrier
  Seventh character (Qualifier) is value Z: No Qualifier

No change: One hundred Ninth panel of table 3 E 0
  Fourth character (Body System / Region) is value M: Peritoneal Cavity
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) is value 0: Antineoplastic
  Seventh character (Qualifier) has 4 choices.
    First choice is value 4: Liquid Brachytherapy Radioisotope
    Second choice is value 5: Other Antineoplastic
    Third choice is value M: Monoclonal Antibody
    Fourth choice is value Y: Hyperthermic

No change: One hundred Tenth panel of table 3 E 0
  Fourth character (Body System / Region) is value M: Peritoneal Cavity
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) is value 2: Anti-infective
  Seventh character (Qualifier) has 2 choices.
    First choice is value 8: Oxazolidinones
    Second choice is value 9: Other Anti-infective

No change: One hundred Eleventh panel of table 3 E 0
  Fourth character (Body System / Region) is value M: Peritoneal Cavity
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) has 9 choices.
    First choice is value 3: Anti-inflammatory
    Second choice is value 5: Adhesion Barrier
    Third choice is value 6: Nutritional Substance
    Fourth choice is value 7: Electrolytic and Water Balance Substance
    Fifth choice is value B: Anesthetic Agent
    Sixth choice is value H: Radioactive Substance
    Seventh choice is value K: Other Diagnostic Substance
    Eighth choice is value N: Analgesics, Hypnotics, Sedatives
    Ninth choice is value T: Destructive Agent
  Seventh character (Qualifier) is value Z: No Qualifier

No change: One hundred Twelfth panel of table 3 E 0
  Fourth character (Body System / Region) is value M: Peritoneal Cavity
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) is value G: Other Therapeutic Substance
  Seventh character (Qualifier) is value C: Other Substance

No change: One hundred Thirteenth panel of table 3 E 0
  Fourth character (Body System / Region) is value M: Peritoneal Cavity
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) is value S: Gas
  Seventh character (Qualifier) is value F: Other Gas

No change: One hundred Fourteenth panel of table 3 E 0
  Fourth character (Body System / Region) is value M: Peritoneal Cavity
  Fifth character (Approach) is value 4: Percutaneous Endoscopic
  Sixth character (Substance) is value 5: Adhesion Barrier
  Seventh character (Qualifier) is value Z: No Qualifier

No change: One hundred Fifteenth panel of table 3 E 0
  Fourth character (Body System / Region) is value M: Peritoneal Cavity
  Fifth character (Approach) is value 4: Percutaneous Endoscopic
  Sixth character (Substance) is value G: Other Therapeutic Substance
  Seventh character (Qualifier) is value C: Other Substance

No change: One hundred Sixteenth panel of table 3 E 0
  Fourth character (Body System / Region) is value M: Peritoneal Cavity
  Fifth character (Approach) is value 7: Via Natural or Artificial Opening
  Sixth character (Substance) is value 0: Antineoplastic
  Seventh character (Qualifier) has 3 choices.
    First choice is value 4: Liquid Brachytherapy Radioisotope
    Second choice is value 5: Other Antineoplastic
    Third choice is value M: Monoclonal Antibody

No change: One hundred Seventeenth panel of table 3 E 0
  Fourth character (Body System / Region) is value M: Peritoneal Cavity
  Fifth character (Approach) is value 7: Via Natural or Artificial Opening
  Sixth character (Substance) is value S: Gas
  Seventh character (Qualifier) is value F: Other Gas

No change: One hundred Eighteenth panel of table 3 E 0
  Fourth character (Body System / Region) is value P: Female Reproductive
  Fifth character (Approach) is value 0: Open
  Sixth character (Substance) is value 5: Adhesion Barrier
  Seventh character (Qualifier) is value Z: No Qualifier

No change: One hundred Nineteenth panel of table 3 E 0
  Fourth character (Body System / Region) is value P: Female Reproductive
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) is value 0: Antineoplastic
  Seventh character (Qualifier) has 3 choices.
    First choice is value 4: Liquid Brachytherapy Radioisotope
    Second choice is value 5: Other Antineoplastic
    Third choice is value M: Monoclonal Antibody

No change: One hundred Twentieth panel of table 3 E 0
  Fourth character (Body System / Region) is value P: Female Reproductive
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) is value 2: Anti-infective
  Seventh character (Qualifier) has 2 choices.
    First choice is value 8: Oxazolidinones
    Second choice is value 9: Other Anti-infective

No change: One hundred Twenty-first panel of table 3 E 0
  Fourth character (Body System / Region) is value P: Female Reproductive
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) has 11 choices.
    First choice is value 3: Anti-inflammatory
    Second choice is value 5: Adhesion Barrier
    Third choice is value 6: Nutritional Substance
    Fourth choice is value 7: Electrolytic and Water Balance Substance
    Fifth choice is value B: Anesthetic Agent
    Sixth choice is value H: Radioactive Substance
    Seventh choice is value K: Other Diagnostic Substance
    Eighth choice is value L: Sperm
    Ninth choice is value N: Analgesics, Hypnotics, Sedatives
    Tenth choice is value T: Destructive Agent
    Eleventh choice is value V: Hormone
  Seventh character (Qualifier) is value Z: No Qualifier

No change: One hundred Twenty-second panel of table 3 E 0
  Fourth character (Body System / Region) is value P: Female Reproductive
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) is value G: Other Therapeutic Substance
  Seventh character (Qualifier) is value C: Other Substance

No change: One hundred Twenty-third panel of table 3 E 0
  Fourth character (Body System / Region) is value P: Female Reproductive
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) is value Q: Fertilized Ovum
  Seventh character (Qualifier) has 2 choices.
    First choice is value 0: Autologous
    Second choice is value 1: Nonautologous

No change: One hundred Twenty-fourth panel of table 3 E 0
  Fourth character (Body System / Region) is value P: Female Reproductive
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) is value S: Gas
  Seventh character (Qualifier) is value F: Other Gas

No change: One hundred Twenty-fifth panel of table 3 E 0
  Fourth character (Body System / Region) is value P: Female Reproductive
  Fifth character (Approach) is value 4: Percutaneous Endoscopic
  Sixth character (Substance) is value 5: Adhesion Barrier
  Seventh character (Qualifier) is value Z: No Qualifier

No change: One hundred Twenty-sixth panel of table 3 E 0
  Fourth character (Body System / Region) is value P: Female Reproductive
  Fifth character (Approach) is value 4: Percutaneous Endoscopic
  Sixth character (Substance) is value G: Other Therapeutic Substance
  Seventh character (Qualifier) is value C: Other Substance

No change: One hundred Twenty-seventh panel of table 3 E 0
  Fourth character (Body System / Region) is value P: Female Reproductive
  Fifth character (Approach) is value 7: Via Natural or Artificial Opening
  Sixth character (Substance) is value 0: Antineoplastic
  Seventh character (Qualifier) has 3 choices.
    First choice is value 4: Liquid Brachytherapy Radioisotope
    Second choice is value 5: Other Antineoplastic
    Third choice is value M: Monoclonal Antibody

No change: One hundred Twenty-eighth panel of table 3 E 0
  Fourth character (Body System / Region) is value P: Female Reproductive
  Fifth character (Approach) is value 7: Via Natural or Artificial Opening
  Sixth character (Substance) is value 2: Anti-infective
  Seventh character (Qualifier) has 2 choices.
    First choice is value 8: Oxazolidinones
    Second choice is value 9: Other Anti-infective

No change: One hundred Twenty-ninth panel of table 3 E 0
  Fourth character (Body System / Region) is value P: Female Reproductive
  Fifth character (Approach) is value 7: Via Natural or Artificial Opening
  Sixth character (Substance) has 10 choices.
    First choice is value 3: Anti-inflammatory
    Second choice is value 6: Nutritional Substance
    Third choice is value 7: Electrolytic and Water Balance Substance
    Fourth choice is value B: Anesthetic Agent
    Fifth choice is value H: Radioactive Substance
    Sixth choice is value K: Other Diagnostic Substance
    Seventh choice is value L: Sperm
    Eighth choice is value N: Analgesics, Hypnotics, Sedatives
    Ninth choice is value T: Destructive Agent
    Tenth choice is value V: Hormone
  Seventh character (Qualifier) is value Z: No Qualifier

No change: One hundred Thirtieth panel of table 3 E 0
  Fourth character (Body System / Region) is value P: Female Reproductive
  Fifth character (Approach) is value 7: Via Natural or Artificial Opening
  Sixth character (Substance) is value G: Other Therapeutic Substance
  Seventh character (Qualifier) is value C: Other Substance

No change: One hundred Thirty-first panel of table 3 E 0
  Fourth character (Body System / Region) is value P: Female Reproductive
  Fifth character (Approach) is value 7: Via Natural or Artificial Opening
  Sixth character (Substance) is value Q: Fertilized Ovum
  Seventh character (Qualifier) has 2 choices.
    First choice is value 0: Autologous
    Second choice is value 1: Nonautologous

No change: One hundred Thirty-second panel of table 3 E 0
  Fourth character (Body System / Region) is value P: Female Reproductive
  Fifth character (Approach) is value 7: Via Natural or Artificial Opening
  Sixth character (Substance) is value S: Gas
  Seventh character (Qualifier) is value F: Other Gas

No change: One hundred Thirty-third panel of table 3 E 0
  Fourth character (Body System / Region) is value P: Female Reproductive
  Fifth character (Approach) is value 8: Via Natural or Artificial Opening Endoscopic
  Sixth character (Substance) is value 0: Antineoplastic
  Seventh character (Qualifier) has 3 choices.
    First choice is value 4: Liquid Brachytherapy Radioisotope
    Second choice is value 5: Other Antineoplastic
    Third choice is value M: Monoclonal Antibody

No change: One hundred Thirty-fourth panel of table 3 E 0
  Fourth character (Body System / Region) is value P: Female Reproductive
  Fifth character (Approach) is value 8: Via Natural or Artificial Opening Endoscopic
  Sixth character (Substance) is value 2: Anti-infective
  Seventh character (Qualifier) has 2 choices.
    First choice is value 8: Oxazolidinones
    Second choice is value 9: Other Anti-infective

No change: One hundred Thirty-fifth panel of table 3 E 0
  Fourth character (Body System / Region) is value P: Female Reproductive
  Fifth character (Approach) is value 8: Via Natural or Artificial Opening Endoscopic
  Sixth character (Substance) has 8 choices.
    First choice is value 3: Anti-inflammatory
    Second choice is value 6: Nutritional Substance
    Third choice is value 7: Electrolytic and Water Balance Substance
    Fourth choice is value B: Anesthetic Agent
    Fifth choice is value H: Radioactive Substance
    Sixth choice is value K: Other Diagnostic Substance
    Seventh choice is value N: Analgesics, Hypnotics, Sedatives
    Eighth choice is value T: Destructive Agent
  Seventh character (Qualifier) is value Z: No Qualifier

No change: One hundred Thirty-sixth panel of table 3 E 0
  Fourth character (Body System / Region) is value P: Female Reproductive
  Fifth character (Approach) is value 8: Via Natural or Artificial Opening Endoscopic
  Sixth character (Substance) is value G: Other Therapeutic Substance
  Seventh character (Qualifier) is value C: Other Substance

No change: One hundred Thirty-seventh panel of table 3 E 0
  Fourth character (Body System / Region) is value P: Female Reproductive
  Fifth character (Approach) is value 8: Via Natural or Artificial Opening Endoscopic
  Sixth character (Substance) is value S: Gas
  Seventh character (Qualifier) is value F: Other Gas

No change: One hundred Thirty-eighth panel of table 3 E 0
  Fourth character (Body System / Region) is value Q: Cranial Cavity and Brain
  Fifth character (Approach) has 2 choices.
    First choice is value 0: Open
    Second choice is value 3: Percutaneous
  Sixth character (Substance) is value 0: Antineoplastic
  Seventh character (Qualifier) has 3 choices.
    First choice is value 4: Liquid Brachytherapy Radioisotope
    Second choice is value 5: Other Antineoplastic
    Third choice is value M: Monoclonal Antibody

No change: One hundred Thirty-ninth panel of table 3 E 0
  Fourth character (Body System / Region) is value Q: Cranial Cavity and Brain
  Fifth character (Approach) has 2 choices.
    First choice is value 0: Open
    Second choice is value 3: Percutaneous
  Sixth character (Substance) is value 2: Anti-infective
  Seventh character (Qualifier) has 2 choices.
    First choice is value 8: Oxazolidinones
    Second choice is value 9: Other Anti-infective

No change: One hundred Fortieth panel of table 3 E 0
  Fourth character (Body System / Region) is value Q: Cranial Cavity and Brain
  Fifth character (Approach) has 2 choices.
    First choice is value 0: Open
    Second choice is value 3: Percutaneous
  Sixth character (Substance) has 9 choices.
    First choice is value 3: Anti-inflammatory
    Second choice is value 6: Nutritional Substance
    Third choice is value 7: Electrolytic and Water Balance Substance
    Fourth choice is value A: Stem Cells, Embryonic
    Fifth choice is value B: Anesthetic Agent
    Sixth choice is value H: Radioactive Substance
    Seventh choice is value K: Other Diagnostic Substance
    Eighth choice is value N: Analgesics, Hypnotics, Sedatives
    Ninth choice is value T: Destructive Agent
  Seventh character (Qualifier) is value Z: No Qualifier

No change: One hundred Forty-first panel of table 3 E 0
  Fourth character (Body System / Region) is value Q: Cranial Cavity and Brain
  Fifth character (Approach) has 2 choices.
    First choice is value 0: Open
    Second choice is value 3: Percutaneous
  Sixth character (Substance) is value E: Stem Cells, Somatic
  Seventh character (Qualifier) has 2 choices.
    First choice is value 0: Autologous
    Second choice is value 1: Nonautologous

No change: One hundred Forty-second panel of table 3 E 0
  Fourth character (Body System / Region) is value Q: Cranial Cavity and Brain
  Fifth character (Approach) has 2 choices.
    First choice is value 0: Open
    Second choice is value 3: Percutaneous
  Sixth character (Substance) is value G: Other Therapeutic Substance
  Seventh character (Qualifier) is value C: Other Substance

No change: One hundred Forty-third panel of table 3 E 0
  Fourth character (Body System / Region) is value Q: Cranial Cavity and Brain
  Fifth character (Approach) has 2 choices.
    First choice is value 0: Open
    Second choice is value 3: Percutaneous
  Sixth character (Substance) is value S: Gas
  Seventh character (Qualifier) is value F: Other Gas

No change: One hundred Forty-fourth panel of table 3 E 0
  Fourth character (Body System / Region) is value Q: Cranial Cavity and Brain
  Fifth character (Approach) is value 7: Via Natural or Artificial Opening
  Sixth character (Substance) is value 0: Antineoplastic
  Seventh character (Qualifier) has 3 choices.
    First choice is value 4: Liquid Brachytherapy Radioisotope
    Second choice is value 5: Other Antineoplastic
    Third choice is value M: Monoclonal Antibody

No change: One hundred Forty-fifth panel of table 3 E 0
  Fourth character (Body System / Region) is value Q: Cranial Cavity and Brain
  Fifth character (Approach) is value 7: Via Natural or Artificial Opening
  Sixth character (Substance) is value S: Gas
  Seventh character (Qualifier) is value F: Other Gas

No change: One hundred Forty-sixth panel of table 3 E 0
  Fourth character (Body System / Region) is value R: Spinal Canal
  Fifth character (Approach) is value 0: Open
  Sixth character (Substance) is value A: Stem Cells, Embryonic
  Seventh character (Qualifier) is value Z: No Qualifier

No change: One hundred Forty-seventh panel of table 3 E 0
  Fourth character (Body System / Region) is value R: Spinal Canal
  Fifth character (Approach) is value 0: Open
  Sixth character (Substance) is value E: Stem Cells, Somatic
  Seventh character (Qualifier) has 2 choices.
    First choice is value 0: Autologous
    Second choice is value 1: Nonautologous

No change: One hundred Forty-eighth panel of table 3 E 0
  Fourth character (Body System / Region) is value R: Spinal Canal
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) is value 0: Antineoplastic
  Seventh character (Qualifier) has 5 choices.
    First choice is value 2: High-dose Interleukin-2
    Second choice is value 3: Low-dose Interleukin-2
    Third choice is value 4: Liquid Brachytherapy Radioisotope
    Fourth choice is value 5: Other Antineoplastic
    Fifth choice is value M: Monoclonal Antibody

No change: One hundred Forty-ninth panel of table 3 E 0
  Fourth character (Body System / Region) is value R: Spinal Canal
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) is value 2: Anti-infective
  Seventh character (Qualifier) has 2 choices.
    First choice is value 8: Oxazolidinones
    Second choice is value 9: Other Anti-infective

No change: One hundred Fiftieth panel of table 3 E 0
  Fourth character (Body System / Region) is value R: Spinal Canal
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) has 9 choices.
    First choice is value 3: Anti-inflammatory
    Second choice is value 6: Nutritional Substance
    Third choice is value 7: Electrolytic and Water Balance Substance
    Fourth choice is value A: Stem Cells, Embryonic
    Fifth choice is value B: Anesthetic Agent
    Sixth choice is value H: Radioactive Substance
    Seventh choice is value K: Other Diagnostic Substance
    Eighth choice is value N: Analgesics, Hypnotics, Sedatives
    Ninth choice is value T: Destructive Agent
  Seventh character (Qualifier) is value Z: No Qualifier

No change: One hundred Fifty-first panel of table 3 E 0
  Fourth character (Body System / Region) is value R: Spinal Canal
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) is value E: Stem Cells, Somatic
  Seventh character (Qualifier) has 2 choices.
    First choice is value 0: Autologous
    Second choice is value 1: Nonautologous

No change: One hundred Fifty-second panel of table 3 E 0
  Fourth character (Body System / Region) is value R: Spinal Canal
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) is value G: Other Therapeutic Substance
  Seventh character (Qualifier) is value C: Other Substance

No change: One hundred Fifty-third panel of table 3 E 0
  Fourth character (Body System / Region) is value R: Spinal Canal
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) is value S: Gas
  Seventh character (Qualifier) is value F: Other Gas

No change: One hundred Fifty-fourth panel of table 3 E 0
  Fourth character (Body System / Region) is value R: Spinal Canal
  Fifth character (Approach) is value 7: Via Natural or Artificial Opening
  Sixth character (Substance) is value S: Gas
  Seventh character (Qualifier) is value F: Other Gas

No change: One hundred Fifty-fifth panel of table 3 E 0
  Fourth character (Body System / Region) is value S: Epidural Space
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) is value 0: Antineoplastic
  Seventh character (Qualifier) has 5 choices.
    First choice is value 2: High-dose Interleukin-2
    Second choice is value 3: Low-dose Interleukin-2
    Third choice is value 4: Liquid Brachytherapy Radioisotope
    Fourth choice is value 5: Other Antineoplastic
    Fifth choice is value M: Monoclonal Antibody

No change: One hundred Fifty-sixth panel of table 3 E 0
  Fourth character (Body System / Region) is value S: Epidural Space
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) is value 2: Anti-infective
  Seventh character (Qualifier) has 2 choices.
    First choice is value 8: Oxazolidinones
    Second choice is value 9: Other Anti-infective

No change: One hundred Fifty-seventh panel of table 3 E 0
  Fourth character (Body System / Region) is value S: Epidural Space
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) has 8 choices.
    First choice is value 3: Anti-inflammatory
    Second choice is value 6: Nutritional Substance
    Third choice is value 7: Electrolytic and Water Balance Substance
    Fourth choice is value B: Anesthetic Agent
    Fifth choice is value H: Radioactive Substance
    Sixth choice is value K: Other Diagnostic Substance
    Seventh choice is value N: Analgesics, Hypnotics, Sedatives
    Eighth choice is value T: Destructive Agent
  Seventh character (Qualifier) is value Z: No Qualifier

No change: One hundred Fifty-eighth panel of table 3 E 0
  Fourth character (Body System / Region) is value S: Epidural Space
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) is value G: Other Therapeutic Substance
  Seventh character (Qualifier) is value C: Other Substance

No change: One hundred Fifty-ninth panel of table 3 E 0
  Fourth character (Body System / Region) is value S: Epidural Space
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) is value S: Gas
  Seventh character (Qualifier) is value F: Other Gas

No change: One hundred Sixtieth panel of table 3 E 0
  Fourth character (Body System / Region) is value S: Epidural Space
  Fifth character (Approach) is value 7: Via Natural or Artificial Opening
  Sixth character (Substance) is value S: Gas
  Seventh character (Qualifier) is value F: Other Gas

No change: One hundred Sixty-first panel of table 3 E 0
  Fourth character (Body System / Region) has 2 choices.
    First choice is value T: Peripheral Nerves and Plexi
    Second choice is value X: Cranial Nerves
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) has 3 choices.
    First choice is value 3: Anti-inflammatory
    Second choice is value B: Anesthetic Agent
    Third choice is value T: Destructive Agent
  Seventh character (Qualifier) is value Z: No Qualifier

No change: One hundred Sixty-second panel of table 3 E 0
  Fourth character (Body System / Region) has 2 choices.
    First choice is value T: Peripheral Nerves and Plexi
    Second choice is value X: Cranial Nerves
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) is value G: Other Therapeutic Substance
  Seventh character (Qualifier) is value C: Other Substance

No change: One hundred Sixty-third panel of table 3 E 0
  Fourth character (Body System / Region) is value U: Joints
  Fifth character (Approach) is value 0: Open
  Sixth character (Substance) is value 2: Anti-infective
  Seventh character (Qualifier) has 2 choices.
    First choice is value 8: Oxazolidinones
    Second choice is value 9: Other Anti-infective

No change: One hundred Sixty-fourth panel of table 3 E 0
  Fourth character (Body System / Region) is value U: Joints
  Fifth character (Approach) is value 0: Open
  Sixth character (Substance) is value G: Other Therapeutic Substance
  Seventh character (Qualifier) has 2 choices.
    First choice is value B: Recombinant Bone Morphogenetic Protein
    Second choice is value C: Other Substance

No change: One hundred Sixty-fifth panel of table 3 E 0
  Fourth character (Body System / Region) is value U: Joints
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) is value 0: Antineoplastic
  Seventh character (Qualifier) has 3 choices.
    First choice is value 4: Liquid Brachytherapy Radioisotope
    Second choice is value 5: Other Antineoplastic
    Third choice is value M: Monoclonal Antibody

No change: One hundred Sixty-sixth panel of table 3 E 0
  Fourth character (Body System / Region) is value U: Joints
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) is value 2: Anti-infective
  Seventh character (Qualifier) has 2 choices.
    First choice is value 8: Oxazolidinones
    Second choice is value 9: Other Anti-infective

No change: One hundred Sixty-seventh panel of table 3 E 0
  Fourth character (Body System / Region) is value U: Joints
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) has 8 choices.
    First choice is value 3: Anti-inflammatory
    Second choice is value 6: Nutritional Substance
    Third choice is value 7: Electrolytic and Water Balance Substance
    Fourth choice is value B: Anesthetic Agent
    Fifth choice is value H: Radioactive Substance
    Sixth choice is value K: Other Diagnostic Substance
    Seventh choice is value N: Analgesics, Hypnotics, Sedatives
    Eighth choice is value T: Destructive Agent
  Seventh character (Qualifier) is value Z: No Qualifier

No change: One hundred Sixty-eighth panel of table 3 E 0
  Fourth character (Body System / Region) is value U: Joints
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) is value G: Other Therapeutic Substance
  Seventh character (Qualifier) has 2 choices.
    First choice is value B: Recombinant Bone Morphogenetic Protein
    Second choice is value C: Other Substance

No change: One hundred Sixty-ninth panel of table 3 E 0
  Fourth character (Body System / Region) is value U: Joints
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) is value S: Gas
  Seventh character (Qualifier) is value F: Other Gas

No change: One hundred Seventieth panel of table 3 E 0
  Fourth character (Body System / Region) is value U: Joints
  Fifth character (Approach) is value 4: Percutaneous Endoscopic
  Sixth character (Substance) is value G: Other Therapeutic Substance
  Seventh character (Qualifier) is value C: Other Substance

No change: One hundred Seventy-first panel of table 3 E 0
  Fourth character (Body System / Region) is value V: Bones
  Fifth character (Approach) is value 0: Open
  Sixth character (Substance) is value G: Other Therapeutic Substance
  Seventh character (Qualifier) has 2 choices.
    First choice is value B: Recombinant Bone Morphogenetic Protein
    Second choice is value C: Other Substance

No change: One hundred Seventy-second panel of table 3 E 0
  Fourth character (Body System / Region) is value V: Bones
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) is value 0: Antineoplastic
  Seventh character (Qualifier) has 2 choices.
    First choice is value 5: Other Antineoplastic
    Second choice is value M: Monoclonal Antibody

No change: One hundred Seventy-third panel of table 3 E 0
  Fourth character (Body System / Region) is value V: Bones
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) is value 2: Anti-infective
  Seventh character (Qualifier) has 2 choices.
    First choice is value 8: Oxazolidinones
    Second choice is value 9: Other Anti-infective

No change: One hundred Seventy-fourth panel of table 3 E 0
  Fourth character (Body System / Region) is value V: Bones
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) has 8 choices.
    First choice is value 3: Anti-inflammatory
    Second choice is value 6: Nutritional Substance
    Third choice is value 7: Electrolytic and Water Balance Substance
    Fourth choice is value B: Anesthetic Agent
    Fifth choice is value H: Radioactive Substance
    Sixth choice is value K: Other Diagnostic Substance
    Seventh choice is value N: Analgesics, Hypnotics, Sedatives
    Eighth choice is value T: Destructive Agent
  Seventh character (Qualifier) is value Z: No Qualifier

No change: One hundred Seventy-fifth panel of table 3 E 0
  Fourth character (Body System / Region) is value V: Bones
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) is value G: Other Therapeutic Substance
  Seventh character (Qualifier) has 2 choices.
    First choice is value B: Recombinant Bone Morphogenetic Protein
    Second choice is value C: Other Substance

No change: One hundred Seventy-sixth panel of table 3 E 0
  Fourth character (Body System / Region) is value V: Bones
  Fifth character (Approach) is value 4: Percutaneous Endoscopic
  Sixth character (Substance) is value G: Other Therapeutic Substance
  Seventh character (Qualifier) is value C: Other Substance

No change: One hundred Seventy-seventh panel of table 3 E 0
  Fourth character (Body System / Region) is value W: Lymphatics
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) is value 0: Antineoplastic
  Seventh character (Qualifier) has 2 choices.
    First choice is value 5: Other Antineoplastic
    Second choice is value M: Monoclonal Antibody

No change: One hundred Seventy-eighth panel of table 3 E 0
  Fourth character (Body System / Region) is value W: Lymphatics
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) is value 2: Anti-infective
  Seventh character (Qualifier) has 2 choices.
    First choice is value 8: Oxazolidinones
    Second choice is value 9: Other Anti-infective

No change: One hundred Seventy-ninth panel of table 3 E 0
  Fourth character (Body System / Region) is value W: Lymphatics
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) has 8 choices.
    First choice is value 3: Anti-inflammatory
    Second choice is value 6: Nutritional Substance
    Third choice is value 7: Electrolytic and Water Balance Substance
    Fourth choice is value B: Anesthetic Agent
    Fifth choice is value H: Radioactive Substance
    Sixth choice is value K: Other Diagnostic Substance
    Seventh choice is value N: Analgesics, Hypnotics, Sedatives
    Eighth choice is value T: Destructive Agent
  Seventh character (Qualifier) is value Z: No Qualifier

No change: One hundred Eightieth panel of table 3 E 0
  Fourth character (Body System / Region) is value W: Lymphatics
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) is value G: Other Therapeutic Substance
  Seventh character (Qualifier) is value C: Other Substance

No change: One hundred Eighty-first panel of table 3 E 0
  Fourth character (Body System / Region) is value Y: Pericardial Cavity
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) is value 0: Antineoplastic
  Seventh character (Qualifier) has 3 choices.
    First choice is value 4: Liquid Brachytherapy Radioisotope
    Second choice is value 5: Other Antineoplastic
    Third choice is value M: Monoclonal Antibody

No change: One hundred Eighty-second panel of table 3 E 0
  Fourth character (Body System / Region) is value Y: Pericardial Cavity
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) is value 2: Anti-infective
  Seventh character (Qualifier) has 2 choices.
    First choice is value 8: Oxazolidinones
    Second choice is value 9: Other Anti-infective

No change: One hundred Eighty-third panel of table 3 E 0
  Fourth character (Body System / Region) is value Y: Pericardial Cavity
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) has 8 choices.
    First choice is value 3: Anti-inflammatory
    Second choice is value 6: Nutritional Substance
    Third choice is value 7: Electrolytic and Water Balance Substance
    Fourth choice is value B: Anesthetic Agent
    Fifth choice is value H: Radioactive Substance
    Sixth choice is value K: Other Diagnostic Substance
    Seventh choice is value N: Analgesics, Hypnotics, Sedatives
    Eighth choice is value T: Destructive Agent
  Seventh character (Qualifier) is value Z: No Qualifier

No change: One hundred Eighty-fourth panel of table 3 E 0
  Fourth character (Body System / Region) is value Y: Pericardial Cavity
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) is value G: Other Therapeutic Substance
  Seventh character (Qualifier) is value C: Other Substance

No change: One hundred Eighty-fifth panel of table 3 E 0
  Fourth character (Body System / Region) is value Y: Pericardial Cavity
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) is value S: Gas
  Seventh character (Qualifier) is value F: Other Gas

No change: One hundred Eighty-sixth panel of table 3 E 0
  Fourth character (Body System / Region) is value Y: Pericardial Cavity
  Fifth character (Approach) is value 4: Percutaneous Endoscopic
  Sixth character (Substance) is value G: Other Therapeutic Substance
  Seventh character (Qualifier) is value C: Other Substance

No change: One hundred Eighty-seventh panel of table 3 E 0
  Fourth character (Body System / Region) is value Y: Pericardial Cavity
  Fifth character (Approach) is value 7: Via Natural or Artificial Opening
  Sixth character (Substance) is value 0: Antineoplastic
  Seventh character (Qualifier) has 3 choices.
    First choice is value 4: Liquid Brachytherapy Radioisotope
    Second choice is value 5: Other Antineoplastic
    Third choice is value M: Monoclonal Antibody

No change: One hundred Eighty-eighth panel of table 3 E 0
  Fourth character (Body System / Region) is value Y: Pericardial Cavity
  Fifth character (Approach) is value 7: Via Natural or Artificial Opening
  Sixth character (Substance) is value S: Gas
  Seventh character (Qualifier) is value F: Other Gas

No change: table 5 A 0
  First character (Section) is value 5: Extracorporeal or Systemic Assistance and Performance
  Second character (Body System) is value A: Physiological Systems
  Third character (Operation) is value 0: Assistance: Taking over a portion of a physiological function by extracorporeal means

No change: First panel of table 5 A 0
  Fourth character (Body System) is value 2: Cardiac
  Fifth character (Duration) is value 1: Intermittent
  Sixth character (Function) is value 1: Output
  Seventh character (Qualifier) has 4 choices.
    First choice is value 0: Balloon Pump
    Second choice is value 5: Pulsatile Compression
    Third choice is value 6: Other Pump
    Fourth choice is value D: Impeller Pump

No change: Second panel of table 5 A 0
  Fourth character (Body System) is value 2: Cardiac
  Fifth character (Duration) is value 2: Continuous
  Sixth character (Function) is value 1: Output
  Seventh character (Qualifier) has 5 choices.
    First choice is value 0: Balloon Pump
    Second choice is value 5: Pulsatile Compression
    Third choice is value 6: Other Pump
    Fourth choice is value D: Impeller Pump
    Fifth choice is value E: Blood Flow Modulator

No change: Third panel of table 5 A 0
  Fourth character (Body System) is value 2: Cardiac
  Fifth character (Duration) is value 2: Continuous
  Sixth character (Function) is value 2: Oxygenation
  Seventh character (Qualifier) is value C: Supersaturated

FY2027: Fourth panel of table 5 A 0
  Fourth character (Body System) is value 5: Circulatory
  Fifth character (Duration) is value 1: Intermittent
  Sixth character (Function) is value 2: Oxygenation
  Seventh character (Qualifier) is value 1: Hyperbaric

FY2027: Fifth panel of table 5 A 0
  Fourth character (Body System) is value 5: Circulatory
  Fifth character (Duration) is value 2: Continuous
  Sixth character (Function) is value 2: Oxygenation
  Seventh character (Qualifier) is value 1: Hyperbaric

FY2027: Sixth panel of table 5 A 0
  Fourth character (Body System) is value 5: Circulatory
  Fifth character (Duration) is value 2: Continuous
  Sixth character (Function) is value 7: Decompression
  Seventh character (Qualifier) is value D: Impeller Pump

No change: Seventh panel of table 5 A 0
  Fourth character (Body System) is value 5: Circulatory
  Fifth character (Duration) is value A: Intraoperative
  Sixth character (Function) is value 0: Filtration
  Seventh character (Qualifier) is value L: Peripheral Veno-venous

No change: Eighth panel of table 5 A 0
  Fourth character (Body System) is value 5: Circulatory
  Fifth character (Duration) is value A: Intraoperative
  Sixth character (Function) is value 6: Cerebral Embolic Filtration
  Seventh character (Qualifier) has 4 choices.
    First choice is value M: Single Capture Filter
    Second choice is value N: Dual Capture Filter
    Third choice is value P: Single Deflection Filter
    Fourth choice is value Q: Extracorporeal Flow Reversal Circuit

No change: Ninth panel of table 5 A 0
  Fourth character (Body System) is value 9: Respiratory
  Fifth character (Duration) is value 2: Continuous
  Sixth character (Function) is value 0: Filtration
  Seventh character (Qualifier) is value Z: No Qualifier

No change: Tenth panel of table 5 A 0
  Fourth character (Body System) is value 9: Respiratory
  Fifth character (Duration) has 3 choices.
    First choice is value 3: Less than 24 Consecutive Hours
    Second choice is value 4: 24-96 Consecutive Hours
    Third choice is value 5: Greater than 96 Consecutive Hours
  Sixth character (Function) is value 5: Ventilation
  Seventh character (Qualifier) has 6 choices.
    First choice is value 7: Continuous Positive Airway Pressure
    Second choice is value 8: Intermittent Positive Airway Pressure
    Third choice is value 9: Continuous Negative Airway Pressure
    Fourth choice is value A: High Flow/Velocity Cannula
    Fifth choice is value B: Intermittent Negative Airway Pressure
    Sixth choice is value Z: No Qualifier

No change: Eleventh panel of table 5 A 0
  Fourth character (Body System) is value 9: Respiratory
  Fifth character (Duration) has 3 choices.
    First choice is value B: Less than 8 Consecutive Hours
    Second choice is value C: 8-24 Consecutive Hours
    Third choice is value D: Greater than 24 Consecutive Hours
  Sixth character (Function) is value 5: Ventilation
  Seventh character (Qualifier) is value K: Intubated Prone Positioning

No change: table 5 A 1
  First character (Section) is value 5: Extracorporeal or Systemic Assistance and Performance
  Second character (Body System) is value A: Physiological Systems
  Third character (Operation) is value 1: Performance: Completely taking over a physiological function by extracorporeal means

No change: First panel of table 5 A 1
  Fourth character (Body System) is value 2: Cardiac
  Fifth character (Duration) is value 0: Single
  Sixth character (Function) is value 1: Output
  Seventh character (Qualifier) is value 2: Manual

No change: Second panel of table 5 A 1
  Fourth character (Body System) is value 2: Cardiac
  Fifth character (Duration) is value 1: Intermittent
  Sixth character (Function) is value 3: Pacing
  Seventh character (Qualifier) is value Z: No Qualifier

No change: Third panel of table 5 A 1
  Fourth character (Body System) is value 2: Cardiac
  Fifth character (Duration) is value 2: Continuous
  Sixth character (Function) is value 1: Output
  Seventh character (Qualifier) has 2 choices.
    First choice is value J: Automated
    Second choice is value Z: No Qualifier

No change: Fourth panel of table 5 A 1
  Fourth character (Body System) is value 2: Cardiac
  Fifth character (Duration) is value 2: Continuous
  Sixth character (Function) is value 3: Pacing
  Seventh character (Qualifier) is value Z: No Qualifier

No change: Fifth panel of table 5 A 1
  Fourth character (Body System) is value 5: Circulatory
  Fifth character (Duration) has 2 choices.
    First choice is value 2: Continuous
    Second choice is value A: Intraoperative
  Sixth character (Function) is value 2: Oxygenation
  Seventh character (Qualifier) has 3 choices.
    First choice is value F: Membrane, Central
    Second choice is value G: Membrane, Peripheral Veno-arterial
    Third choice is value H: Membrane, Peripheral Veno-venous

No change: Sixth panel of table 5 A 1
  Fourth character (Body System) is value 9: Respiratory
  Fifth character (Duration) is value 0: Single
  Sixth character (Function) is value 5: Ventilation
  Seventh character (Qualifier) is value 4: Nonmechanical

No change: Seventh panel of table 5 A 1
  Fourth character (Body System) is value 9: Respiratory
  Fifth character (Duration) has 3 choices.
    First choice is value 3: Less than 24 Consecutive Hours
    Second choice is value 4: 24-96 Consecutive Hours
    Third choice is value 5: Greater than 96 Consecutive Hours
  Sixth character (Function) is value 5: Ventilation
  Seventh character (Qualifier) is value Z: No Qualifier

No change: Eighth panel of table 5 A 1
  Fourth character (Body System) is value C: Biliary
  Fifth character (Duration) has 2 choices.
    First choice is value 0: Single
    Second choice is value 6: Multiple
  Sixth character (Function) is value 0: Filtration
  Seventh character (Qualifier) is value Z: No Qualifier

FY2027: Ninth panel of table 5 A 1
  Fourth character (Body System) is value D: Urinary
  Fifth character (Duration) has 3 choices.
    First choice is value 7: Intermittent, Less than 6 Hours Per Day
    Second choice is value 8: Prolonged Intermittent, 6-18 hours Per Day
    Third choice is value 9: Continuous, Greater than 18 hours Per Day
  Sixth character (Function) is value 0: Filtration
  Seventh character (Qualifier) has 2 choices.
    First choice is value 1: Selective Cytopheresis
    Second choice is value Z: No Qualifier

FY2027: table B 8 5
  First character (Section) is value B: Imaging
  Second character (Body System) is value 8: Eye
  Third character (Type) is value 5: Other Imaging: Other specified modality for visualizing a body part

FY2027: First panel of table B 8 5
  Fourth character (Body Part) has 4 choices.
    First choice is value A: Choroid, Right
    Second choice is value B: Choroid, Left
    Third choice is value G: Retinal Vessel, Right
    Fourth choice is value H: Retinal Vessel, Left
  Fifth character (Contrast) is value 2: Fluorescing Agent
  Sixth character (Qualifier) is value Z: None
  Seventh character (Qualifier) is value Z: None

No change: table X 0 H
  First character (Section) is value X: New Technology
  Second character (Body System) is value 0: Nervous System
  Third character (Operation) is value H: Insertion: Putting in a nonbiological appliance that monitors, assists, performs, or prevents a physiological function but does not physically take the place of a body part

No change: First panel of table X 0 H
  Fourth character (Body Part) is value K: Sphenopalatine Ganglion
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value Q: Neurostimulator Lead
  Seventh character (Qualifier) is value 8: New Technology Group 8

FY2027: Second panel of table X 0 H
  Fourth character (Body Part) is value Q: Vagus Nerve
  Fifth character (Approach) is value 0: Open
  Sixth character (Device / Substance / Technology) is value 5: Leadless Neurostimulator Generator
  Seventh character (Qualifier) is value C: New Technology Group 12

No change: Third panel of table X 0 H
  Fourth character (Body Part) is value Q: Vagus Nerve
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value R: Neurostimulator Lead with Paired Stimulation System
  Seventh character (Qualifier) is value 8: New Technology Group 8

No change: table X 2 7
  First character (Section) is value X: New Technology
  Second character (Body System) is value 2: Cardiovascular System
  Third character (Operation) is value 7: Dilation: Expanding an orifice or the lumen of a tubular body part

No change: First panel of table X 2 7
  Fourth character (Body Part) is value 2: Inferior Vena Cava and Iliocaval Confluence
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value C: Intraluminal Device, Open-structure Polymer Lattice
  Seventh character (Qualifier) is value B: New Technology Group 11

No change: Second panel of table X 2 7
  Fourth character (Body Part) has 2 choices.
    First choice is value 3: Pulmonary Artery, Right
    Second choice is value 4: Pulmonary Artery, Left
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value 9: Intraluminal Device, Expandable
  Seventh character (Qualifier) is value B: New Technology Group 11

No change: Third panel of table X 2 7
  Fourth character (Body Part) has 10 choices.
    First choice is value 5: Subclavian Vein, Right
    Second choice is value 6: Subclavian Vein, Left
    Third choice is value 7: Axillary Vein, Right
    Fourth choice is value 8: Axillary Vein, Left
    Fifth choice is value 9: Brachial Vein, Right
    Sixth choice is value A: Brachial Vein, Left
    Seventh choice is value B: Basilic Vein, Right
    Eighth choice is value C: Basilic Vein, Left
    Ninth choice is value D: Cephalic Vein, Right
    Tenth choice is value E: Cephalic Vein, Left
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value 5: Intraluminal Device, Cell Impermeable
  Seventh character (Qualifier) is value B: New Technology Group 11

FY2027: Fourth panel of table X 2 7
  Fourth character (Body Part) is value P: Anterior Tibial Artery, Right
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value N: Intraluminal Device(s), Small-diameter
  Seventh character (Qualifier) is value C: New Technology Group 12

FY2027: Fifth panel of table X 2 7
  Fourth character (Body Part) is value P: Anterior Tibial Artery, Right
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value T: Intraluminal Device, Everolimus-eluting Resorbable Scaffold(s)
  Seventh character (Qualifier) is value A: New Technology Group 10

FY2027: Sixth panel of table X 2 7
  Fourth character (Body Part) is value Q: Anterior Tibial Artery, Left
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value N: Intraluminal Device(s), Small-diameter
  Seventh character (Qualifier) is value C: New Technology Group 12

FY2027: Seventh panel of table X 2 7
  Fourth character (Body Part) is value Q: Anterior Tibial Artery, Left
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value T: Intraluminal Device, Everolimus-eluting Resorbable Scaffold(s)
  Seventh character (Qualifier) is value A: New Technology Group 10

FY2027: Eighth panel of table X 2 7
  Fourth character (Body Part) is value R: Posterior Tibial Artery, Right
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value N: Intraluminal Device(s), Small-diameter
  Seventh character (Qualifier) is value C: New Technology Group 12

FY2027: Ninth panel of table X 2 7
  Fourth character (Body Part) is value R: Posterior Tibial Artery, Right
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value T: Intraluminal Device, Everolimus-eluting Resorbable Scaffold(s)
  Seventh character (Qualifier) is value A: New Technology Group 10

FY2027: Tenth panel of table X 2 7
  Fourth character (Body Part) is value S: Posterior Tibial Artery, Left
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value N: Intraluminal Device(s), Small-diameter
  Seventh character (Qualifier) is value C: New Technology Group 12

FY2027: Eleventh panel of table X 2 7
  Fourth character (Body Part) is value S: Posterior Tibial Artery, Left
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value T: Intraluminal Device, Everolimus-eluting Resorbable Scaffold(s)
  Seventh character (Qualifier) is value A: New Technology Group 10

FY2027: Twelfth panel of table X 2 7
  Fourth character (Body Part) is value T: Peroneal Artery, Right
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value N: Intraluminal Device(s), Small-diameter
  Seventh character (Qualifier) is value C: New Technology Group 12

FY2027: Thirteenth panel of table X 2 7
  Fourth character (Body Part) is value T: Peroneal Artery, Right
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value T: Intraluminal Device, Everolimus-eluting Resorbable Scaffold(s)
  Seventh character (Qualifier) is value A: New Technology Group 10

FY2027: Fourteenth panel of table X 2 7
  Fourth character (Body Part) is value U: Peroneal Artery, Left
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value N: Intraluminal Device(s), Small-diameter
  Seventh character (Qualifier) is value C: New Technology Group 12

FY2027: Fifteenth panel of table X 2 7
  Fourth character (Body Part) is value U: Peroneal Artery, Left
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value T: Intraluminal Device, Everolimus-eluting Resorbable Scaffold(s)
  Seventh character (Qualifier) is value A: New Technology Group 10

No change: Sixteenth panel of table X 2 7
  Fourth character (Body Part) has 2 choices.
    First choice is value W: Thoracic Aorta, Descending
    Second choice is value X: Thoracic Aorta, Ascending/Arch
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value 9: Intraluminal Device, Expandable
  Seventh character (Qualifier) is value B: New Technology Group 11

No change: table X 2 8
  First character (Section) is value X: New Technology
  Second character (Body System) is value 2: Cardiovascular System
  Third character (Operation) is value 8: Division: Cutting into a body part, without draining fluids and/or gases from the body part, in order to separate or transect a body part

No change: First panel of table X 2 8
  Fourth character (Body Part) is value F: Aortic Valve
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value V: Intraluminal Bioprosthetic Valve Leaflet Splitting Technology in Existing Valve
  Seventh character (Qualifier) is value A: New Technology Group 10

No change: Second panel of table X 2 8
  Fourth character (Body Part) is value F: Aortic Valve
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value W: Leaflet Laceration, Radiofrequency Energy
  Seventh character (Qualifier) is value B: New Technology Group 11

FY2027: Third panel of table X 2 8
  Fourth character (Body Part) is value M: Ventricular Septum
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value D: Transcatheter Septal Scoring Technique
  Seventh character (Qualifier) is value C: New Technology Group 12

No change: table X 2 H
  First character (Section) is value X: New Technology
  Second character (Body System) is value 2: Cardiovascular System
  Third character (Operation) is value H: Insertion: Putting in a nonbiological appliance that monitors, assists, performs, or prevents a physiological function but does not physically take the place of a body part

No change: First panel of table X 2 H
  Fourth character (Body Part) is value 0: Inferior Vena Cava
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value B: Volume Sensor Management Device
  Seventh character (Qualifier) is value B: New Technology Group 11

No change: Second panel of table X 2 H
  Fourth character (Body Part) has 2 choices.
    First choice is value 0: Inferior Vena Cava
    Second choice is value 1: Superior Vena Cava
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value R: Intraluminal Device, Bioprosthetic Valve
  Seventh character (Qualifier) is value 9: New Technology Group 9

No change: Third panel of table X 2 H
  Fourth character (Body Part) is value 1: Superior Vena Cava
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value X: Temporary Phrenic Nerve/Diaphragm Stimulation Electrodes
  Seventh character (Qualifier) is value B: New Technology Group 11

No change: Fourth panel of table X 2 H
  Fourth character (Body Part) has 2 choices.
    First choice is value 2: Femoral Vein, Right
    Second choice is value 3: Femoral Vein, Left
  Fifth character (Approach) is value 0: Open
  Sixth character (Device / Substance / Technology) is value R: Intraluminal Device, Bioprosthetic Valve
  Seventh character (Qualifier) is value 9: New Technology Group 9

FY2027: Fifth panel of table X 2 H
  Fourth character (Body Part) is value 4: Innominate Vein, Left
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value M: Temporary Intraluminal Device, Venous Angle Decompression using Impeller Pump
  Seventh character (Qualifier) is value C: New Technology Group 12

No change: Sixth panel of table X 2 H
  Fourth character (Body Part) has 2 choices.
    First choice is value 6: Atrium, Right
    Second choice is value K: Ventricle, Right
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value V: Intracardiac Pacemaker, Dual-Chamber
  Seventh character (Qualifier) is value 9: New Technology Group 9

No change: Seventh panel of table X 2 H
  Fourth character (Body Part) has 2 choices.
    First choice is value L: Axillary Artery, Right
    Second choice is value M: Axillary Artery, Left
  Fifth character (Approach) is value 0: Open
  Sixth character (Device / Substance / Technology) is value F: Conduit to Short-term External Heart Assist System
  Seventh character (Qualifier) is value 9: New Technology Group 9

No change: Eighth panel of table X 2 H
  Fourth character (Body Part) has 2 choices.
    First choice is value M: Ventricular Septum
    Second choice is value V: Ventricle, Right
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value G: Defibrillator Lead, Lumenless Small-diameter
  Seventh character (Qualifier) is value B: New Technology Group 11

No change: Ninth panel of table X 2 H
  Fourth character (Body Part) is value N: Ventricle, Left
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value 7: Endocardiac Pacing Electrode
  Seventh character (Qualifier) is value B: New Technology Group 11

No change: Tenth panel of table X 2 H
  Fourth character (Body Part) has 6 choices.
    First choice is value P: Anterior Tibial Artery, Right
    Second choice is value Q: Anterior Tibial Artery, Left
    Third choice is value R: Posterior Tibial Artery, Right
    Fourth choice is value S: Posterior Tibial Artery, Left
    Fifth choice is value T: Peroneal Artery, Right
    Sixth choice is value U: Peroneal Artery, Left
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value 8: Intraluminal Device, Temporary
  Seventh character (Qualifier) is value B: New Technology Group 11

No change: Eleventh panel of table X 2 H
  Fourth character (Body Part) is value X: Thoracic Aorta, Ascending
  Fifth character (Approach) is value 0: Open
  Sixth character (Device / Substance / Technology) is value F: Conduit to Short-term External Heart Assist System
  Seventh character (Qualifier) is value 9: New Technology Group 9

No change: table X 2 R
  First character (Section) is value X: New Technology
  Second character (Body System) is value 2: Cardiovascular System
  Third character (Operation) is value R: Replacement: Putting in or on biological or synthetic material that physically takes the place and/or function of all or a portion of a body part

No change: First panel of table X 2 R
  Fourth character (Body Part) has 4 choices.
    First choice is value 5: Upper Extremity Artery, Right
    Second choice is value 6: Upper Extremity Artery, Left
    Third choice is value 7: Lower Extremity Artery, Right
    Fourth choice is value 8: Lower Extremity Artery, Left
  Fifth character (Approach) is value 0: Open
  Sixth character (Device / Substance / Technology) is value W: Bioengineered Human Acellular Vessel
  Seventh character (Qualifier) is value A: New Technology Group 10

FY2027: Second panel of table X 2 R
  Fourth character (Body Part) is value F: Aortic Valve
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value L: Zooplastic Tissue, with Integrated Native Leaflet Clipping Locators
  Seventh character (Qualifier) is value C: New Technology Group 12

FY2027: Third panel of table X 2 R
  Fourth character (Body Part) is value G: Mitral Valve
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value F: Bioprosthetic Valve, Balloon-expandable with Dock
  Seventh character (Qualifier) is value C: New Technology Group 12

FY2027: Fourth panel of table X 2 R
  Fourth character (Body Part) is value H: Pulmonary Valve
  Fifth character (Approach) is value 0: Open
  Sixth character (Device / Substance / Technology) is value G: Synthetic Substitute, Size-Adjustable
  Seventh character (Qualifier) is value C: New Technology Group 12

No change: Fifth panel of table X 2 R
  Fourth character (Body Part) is value J: Tricuspid Valve
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value R: Multi-plane Flex Technology Bioprosthetic Valve
  Seventh character (Qualifier) is value A: New Technology Group 10

No change: Sixth panel of table X 2 R
  Fourth character (Body Part) is value X: Thoracic Aorta, Arch
  Fifth character (Approach) is value 0: Open
  Sixth character (Device / Substance / Technology) is value N: Branched Synthetic Substitute with Intraluminal Device
  Seventh character (Qualifier) is value 7: New Technology Group 7

No change: table X 2 V
  First character (Section) is value X: New Technology
  Second character (Body System) is value 2: Cardiovascular System
  Third character (Operation) is value V: Restriction: Partially closing an orifice or the lumen of a tubular body part

No change: First panel of table X 2 V
  Fourth character (Body Part) is value 7: Coronary Sinus
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value Q: Reduction Device
  Seventh character (Qualifier) is value 7: New Technology Group 7

No change: Second panel of table X 2 V
  Fourth character (Body Part) is value E: Descending Thoracic Aorta and Abdominal Aorta
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value S: Branched Intraluminal Device, Manufactured Integrated System, Four or More Arteries
  Seventh character (Qualifier) is value A: New Technology Group 10

FY2027: Third panel of table X 2 V
  Fourth character (Body Part) is value J: Thoracic Aorta, Ascending and Arch
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value H: Branched Intraluminal Device, Integrated System with Innominate Branch
  Seventh character (Qualifier) is value C: New Technology Group 12

No change: Fourth panel of table X 2 V
  Fourth character (Body Part) is value W: Thoracic Aorta, Descending
  Fifth character (Approach) is value 0: Open
  Sixth character (Device / Substance / Technology) is value N: Branched Synthetic Substitute with Intraluminal Device
  Seventh character (Qualifier) is value 7: New Technology Group 7

FY2027: Fifth panel of table X 2 V
  Fourth character (Body Part) is value W: Thoracic Aorta, Descending
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value J: Branched Intraluminal Device, Integrated System Extension
  Seventh character (Qualifier) is value C: New Technology Group 12

FY2027: Sixth panel of table X 2 V
  Fourth character (Body Part) is value X: Thoracic Aorta, Arch
  Fifth character (Approach) is value 0: Open
  Sixth character (Device / Substance / Technology) is value K: Branched Intraluminal Device, with Conical Collar
  Seventh character (Qualifier) is value C: New Technology Group 12

No change: Seventh panel of table X 2 V
  Fourth character (Body Part) is value Y: Thoracic Aortic Arch and Descending Thoracic Aorta
  Fifth character (Approach) is value 0: Open
  Sixth character (Device / Substance / Technology) is value 6: Intraluminal Device, Uncovered with Support Cuff
  Seventh character (Qualifier) is value B: New Technology Group 11

FY2026: table X D 2
  First character (Section) is value X: New Technology
  Second character (Body System) is value D: Gastrointestinal System
  Third character (Operation) is value 2: Monitoring: Determining the level of a physiological or physical function repetitively over a period of time

FY2027: table X E Z
  First character (Section) is value X: New Technology
  Second character (Body System) is value E: Physiological Systems and Anatomical Regions
  Third character (Operation) is value Z: Other Procedures: Methodologies which attempt to remediate or cure a disorder or disease

FY2027: First panel of table X E Z
  Fourth character (Body Part) is value 5: Chest, Abdomen and Pelvis
  Fifth character (Approach) is value X: External
  Sixth character (Device / Substance / Technology) is value K: Computer-Aided Triage and Notification for Imaging Abnormalities in Computed Tomography
  Seventh character (Qualifier) is value C: New Technology Group 12

FY2027: Second panel of table X E Z
  Fourth character (Body Part) is value D: Pericardial Cavity
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value Q: Pericardial Cavity Access using Blunt-tip Concealed Needle with Mechanical Gripping Mechanism
  Seventh character (Qualifier) is value C: New Technology Group 12

FY2027: Third panel of table X E Z
  Fourth character (Body Part) is value J: Coronary Artery/Arteries
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value N: Coronary Artery Access using Image-Guided Crossing and Re-entry System
  Seventh character (Qualifier) is value C: New Technology Group 12

FY2027: Fourth panel of table X E Z
  Fourth character (Body Part) is value U: Spinal Canal
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value H: Computer-Aided Guidance for Intraprocedural Navigation using Ultrasound Imaging with Continuous Needle Tracking
  Seventh character (Qualifier) is value C: New Technology Group 12

FY2027: Fifth panel of table X E Z
  Fourth character (Body Part) is value Z: None
  Fifth character (Approach) is value X: External
  Sixth character (Device / Substance / Technology) has 6 choices.
    First choice is value J: High Dimensional Mixture-of-Experts Computer-aided Assessment of Inflammatory Response and Organ Function, for Notification and Triage
    Second choice is value L: Computer-Aided Detection and Notification for Imaging Abnormalities in Echocardiography
    Third choice is value M: Computer-Aided Detection and Notification for Abnormalities in Electrocardiogram
    Fourth choice is value P: Cardiac Conduction Mechanism, Computer-aided Guidance for Three Dimensional Intraprocedural Navigation using Fluoroscopic Imaging
    Fifth choice is value R: Computer-Aided Detection and Notification of Cardiac Abnormalities using Vital Signs
    Sixth choice is value S: Cardiac Conduction Mechanism, Computer-aided Intraprocedural Visualization for Guidance
  Seventh character (Qualifier) is value C: New Technology Group 12

No change: table X F J
  First character (Section) is value X: New Technology
  Second character (Body System) is value F: Hepatobiliary System and Pancreas
  Third character (Operation) is value J: Inspection: Visually and/or manually exploring a body part

FY2027: First panel of table X F J
  Fourth character (Body Part) is value B: Hepatobiliary Duct
  Fifth character (Approach) has 2 choices.
    First choice is value 3: Percutaneous
    Second choice is value 4: Percutaneous Endoscopic
  Sixth character (Device / Substance / Technology) is value C: Single-use Choledochoscope
  Seventh character (Qualifier) is value C: New Technology Group 12

FY2027: Second panel of table X F J
  Fourth character (Body Part) is value B: Hepatobiliary Duct
  Fifth character (Approach) is value 8: Via Natural or Artificial Opening Endoscopic
  Sixth character (Device / Substance / Technology) is value A: Single-use Duodenoscope
  Seventh character (Qualifier) is value 7: New Technology Group 7

FY2027: Third panel of table X F J
  Fourth character (Body Part) is value B: Hepatobiliary Duct
  Fifth character (Approach) is value 8: Via Natural or Artificial Opening Endoscopic
  Sixth character (Device / Substance / Technology) is value B: Single-use Cholangioscope
  Seventh character (Qualifier) is value C: New Technology Group 12

FY2027: Fourth panel of table X F J
  Fourth character (Body Part) is value D: Pancreatic Duct
  Fifth character (Approach) has 2 choices.
    First choice is value 3: Percutaneous
    Second choice is value 4: Percutaneous Endoscopic
  Sixth character (Device / Substance / Technology) is value C: Single-use Choledochoscope
  Seventh character (Qualifier) is value C: New Technology Group 12

FY2027: Fifth panel of table X F J
  Fourth character (Body Part) is value D: Pancreatic Duct
  Fifth character (Approach) is value 8: Via Natural or Artificial Opening Endoscopic
  Sixth character (Device / Substance / Technology) is value A: Single-use Duodenoscope
  Seventh character (Qualifier) is value 7: New Technology Group 7

FY2027: Sixth panel of table X F J
  Fourth character (Body Part) is value D: Pancreatic Duct
  Fifth character (Approach) is value 8: Via Natural or Artificial Opening Endoscopic
  Sixth character (Device / Substance / Technology) is value B: Single-use Cholangioscope
  Seventh character (Qualifier) is value C: New Technology Group 12

No change: table X H H
  First character (Section) is value X: New Technology
  Second character (Body System) is value H: Skin, Subcutaneous Tissue, Fascia and Breast
  Third character (Operation) is value H: Insertion: Putting in a nonbiological appliance that monitors, assists, performs, or prevents a physiological function but does not physically take the place of a body part

No change: First panel of table X H H
  Fourth character (Body Part) is value 8: Subcutaneous Tissue and Fascia, Chest
  Fifth character (Approach) is value 0: Open
  Sixth character (Device / Substance / Technology) is value H: Ultrasound Transmitter and Battery for Endocardiac Pacing Electrode
  Seventh character (Qualifier) is value B: New Technology Group 11

FY2027: Second panel of table X H H
  Fourth character (Body Part) is value 8: Subcutaneous Tissue and Fascia, Chest
  Fifth character (Approach) is value 0: Open
  Sixth character (Device / Substance / Technology) is value J: Contractility Modulation Device with Defibrillator Generator
  Seventh character (Qualifier) is value C: New Technology Group 12

No change: table X R G
  First character (Section) is value X: New Technology
  Second character (Body System) is value R: Joints
  Third character (Operation) is value G: Fusion: Joining together portions of an articular body part rendering the articular body part immobile

No change: First panel of table X R G
  Fourth character (Body Part) has 3 choices.
    First choice is value 1: Cervical Vertebral Joint
    Second choice is value 2: Cervical Vertebral Joints, 2 or more
    Third choice is value 4: Cervicothoracic Vertebral Joint
  Fifth character (Approach) has 3 choices.
    First choice is value 0: Open
    Second choice is value 3: Percutaneous
    Third choice is value 4: Percutaneous Endoscopic
  Sixth character (Device / Substance / Technology) is value R: Interbody Fusion Device, Custom-Made Anatomically Designed
  Seventh character (Qualifier) is value B: New Technology Group 11

FY2027: Second panel of table X R G
  Fourth character (Body Part) has 4 choices.
    First choice is value A: Thoracolumbar Vertebral Joint
    Second choice is value B: Lumbar Vertebral Joint
    Third choice is value C: Lumbar Vertebral Joints, 2 or more
    Fourth choice is value D: Lumbosacral Joint
  Fifth character (Approach) is value 0: Open
  Sixth character (Device / Substance / Technology) is value E: Facet Joint Fusion Device, Paired Titanium Cages
  Seventh character (Qualifier) is value A: New Technology Group 10

No change: Third panel of table X R G
  Fourth character (Body Part) is value E: Sacroiliac Joint, Right
  Fifth character (Approach) is value 0: Open
  Sixth character (Device / Substance / Technology) is value 5: Internal Fixation Device with Tulip Connector
  Seventh character (Qualifier) is value 8: New Technology Group 8

No change: Fourth panel of table X R G
  Fourth character (Body Part) is value E: Sacroiliac Joint, Right
  Fifth character (Approach) is value 0: Open
  Sixth character (Device / Substance / Technology) is value H: Internal Fixation Device, Bone-Density-Specific Thread and Porosity Pattern
  Seventh character (Qualifier) is value B: New Technology Group 11

No change: Fifth panel of table X R G
  Fourth character (Body Part) is value E: Sacroiliac Joint, Right
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value 5: Internal Fixation Device with Tulip Connector
  Seventh character (Qualifier) is value 8: New Technology Group 8

No change: Sixth panel of table X R G
  Fourth character (Body Part) is value E: Sacroiliac Joint, Right
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value H: Internal Fixation Device, Bone-Density-Specific Thread and Porosity Pattern
  Seventh character (Qualifier) is value B: New Technology Group 11

No change: Seventh panel of table X R G
  Fourth character (Body Part) is value F: Sacroiliac Joint, Left
  Fifth character (Approach) is value 0: Open
  Sixth character (Device / Substance / Technology) is value 5: Internal Fixation Device with Tulip Connector
  Seventh character (Qualifier) is value 8: New Technology Group 8

No change: Eighth panel of table X R G
  Fourth character (Body Part) is value F: Sacroiliac Joint, Left
  Fifth character (Approach) is value 0: Open
  Sixth character (Device / Substance / Technology) is value H: Internal Fixation Device, Bone-Density-Specific Thread and Porosity Pattern
  Seventh character (Qualifier) is value B: New Technology Group 11

No change: Ninth panel of table X R G
  Fourth character (Body Part) is value F: Sacroiliac Joint, Left
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value 5: Internal Fixation Device with Tulip Connector
  Seventh character (Qualifier) is value 8: New Technology Group 8

No change: Tenth panel of table X R G
  Fourth character (Body Part) is value F: Sacroiliac Joint, Left
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value H: Internal Fixation Device, Bone-Density-Specific Thread and Porosity Pattern
  Seventh character (Qualifier) is value B: New Technology Group 11

No change: Eleventh panel of table X R G
  Fourth character (Body Part) is value J: Ankle Joint, Right
  Fifth character (Approach) is value 0: Open
  Sixth character (Device / Substance / Technology) is value B: Internal Fixation Device, Open-truss Design
  Seventh character (Qualifier) is value 9: New Technology Group 9

No change: Twelfth panel of table X R G
  Fourth character (Body Part) is value J: Ankle Joint, Right
  Fifth character (Approach) is value 0: Open
  Sixth character (Device / Substance / Technology) is value C: Internal Fixation Device, Gyroid-Sheet Lattice Design
  Seventh character (Qualifier) is value A: New Technology Group 10

No change: Thirteenth panel of table X R G
  Fourth character (Body Part) is value K: Ankle Joint, Left
  Fifth character (Approach) is value 0: Open
  Sixth character (Device / Substance / Technology) is value B: Internal Fixation Device, Open-truss Design
  Seventh character (Qualifier) is value 9: New Technology Group 9

No change: Fourteenth panel of table X R G
  Fourth character (Body Part) is value K: Ankle Joint, Left
  Fifth character (Approach) is value 0: Open
  Sixth character (Device / Substance / Technology) is value C: Internal Fixation Device, Gyroid-Sheet Lattice Design
  Seventh character (Qualifier) is value A: New Technology Group 10

No change: Fifteenth panel of table X R G
  Fourth character (Body Part) is value L: Tarsal Joint, Right
  Fifth character (Approach) is value 0: Open
  Sixth character (Device / Substance / Technology) is value B: Internal Fixation Device, Open-truss Design
  Seventh character (Qualifier) is value 9: New Technology Group 9

No change: Sixteenth panel of table X R G
  Fourth character (Body Part) is value L: Tarsal Joint, Right
  Fifth character (Approach) is value 0: Open
  Sixth character (Device / Substance / Technology) is value C: Internal Fixation Device, Gyroid-Sheet Lattice Design
  Seventh character (Qualifier) is value A: New Technology Group 10

No change: Seventeenth panel of table X R G
  Fourth character (Body Part) is value M: Tarsal Joint, Left
  Fifth character (Approach) is value 0: Open
  Sixth character (Device / Substance / Technology) is value B: Internal Fixation Device, Open-truss Design
  Seventh character (Qualifier) is value 9: New Technology Group 9

No change: Eighteenth panel of table X R G
  Fourth character (Body Part) is value M: Tarsal Joint, Left
  Fifth character (Approach) is value 0: Open
  Sixth character (Device / Substance / Technology) is value C: Internal Fixation Device, Gyroid-Sheet Lattice Design
  Seventh character (Qualifier) is value A: New Technology Group 10

No change: table X R H
  First character (Section) is value X: New Technology
  Second character (Body System) is value R: Joints
  Third character (Operation) is value H: Insertion: Putting in a nonbiological appliance that monitors, assists, performs, or prevents a physiological function but does not physically take the place of a body part

FY2027: First panel of table X R H
  Fourth character (Body Part) is value 1: Cervical Vertebral Joint
  Fifth character (Approach) is value 0: Open
  Sixth character (Device / Substance / Technology) is value G: Molybdenum Rhenium Alloy Spinal Stabilization Device
  Seventh character (Qualifier) is value B: New Technology Group 11

FY2027: Second panel of table X R H
  Fourth character (Body Part) is value 1: Cervical Vertebral Joint
  Fifth character (Approach) is value 0: Open
  Sixth character (Device / Substance / Technology) is value N: Carbon/PEEK Spinal Stabilization Device
  Seventh character (Qualifier) is value C: New Technology Group 12

FY2027: Third panel of table X R H
  Fourth character (Body Part) is value 1: Cervical Vertebral Joint
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value G: Molybdenum Rhenium Alloy Spinal Stabilization Device
  Seventh character (Qualifier) is value B: New Technology Group 11

FY2027: Fourth panel of table X R H
  Fourth character (Body Part) is value 1: Cervical Vertebral Joint
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value N: Carbon/PEEK Spinal Stabilization Device
  Seventh character (Qualifier) is value C: New Technology Group 12

FY2027: Fifth panel of table X R H
  Fourth character (Body Part) is value 1: Cervical Vertebral Joint
  Fifth character (Approach) is value 4: Percutaneous Endoscopic
  Sixth character (Device / Substance / Technology) is value G: Molybdenum Rhenium Alloy Spinal Stabilization Device
  Seventh character (Qualifier) is value B: New Technology Group 11

FY2027: Sixth panel of table X R H
  Fourth character (Body Part) is value 1: Cervical Vertebral Joint
  Fifth character (Approach) is value 4: Percutaneous Endoscopic
  Sixth character (Device / Substance / Technology) is value N: Carbon/PEEK Spinal Stabilization Device
  Seventh character (Qualifier) is value C: New Technology Group 12

FY2027: Seventh panel of table X R H
  Fourth character (Body Part) is value 2: Cervical Vertebral Joints, 2 or more
  Fifth character (Approach) is value 0: Open
  Sixth character (Device / Substance / Technology) is value G: Molybdenum Rhenium Alloy Spinal Stabilization Device
  Seventh character (Qualifier) is value B: New Technology Group 11

FY2027: Eighth panel of table X R H
  Fourth character (Body Part) is value 2: Cervical Vertebral Joints, 2 or more
  Fifth character (Approach) is value 0: Open
  Sixth character (Device / Substance / Technology) is value N: Carbon/PEEK Spinal Stabilization Device
  Seventh character (Qualifier) is value C: New Technology Group 12

FY2027: Ninth panel of table X R H
  Fourth character (Body Part) is value 2: Cervical Vertebral Joints, 2 or more
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value G: Molybdenum Rhenium Alloy Spinal Stabilization Device
  Seventh character (Qualifier) is value B: New Technology Group 11

FY2027: Tenth panel of table X R H
  Fourth character (Body Part) is value 2: Cervical Vertebral Joints, 2 or more
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value N: Carbon/PEEK Spinal Stabilization Device
  Seventh character (Qualifier) is value C: New Technology Group 12

FY2027: Eleventh panel of table X R H
  Fourth character (Body Part) is value 2: Cervical Vertebral Joints, 2 or more
  Fifth character (Approach) is value 4: Percutaneous Endoscopic
  Sixth character (Device / Substance / Technology) is value G: Molybdenum Rhenium Alloy Spinal Stabilization Device
  Seventh character (Qualifier) is value B: New Technology Group 11

FY2027: Twelfth panel of table X R H
  Fourth character (Body Part) is value 2: Cervical Vertebral Joints, 2 or more
  Fifth character (Approach) is value 4: Percutaneous Endoscopic
  Sixth character (Device / Substance / Technology) is value N: Carbon/PEEK Spinal Stabilization Device
  Seventh character (Qualifier) is value C: New Technology Group 12

FY2027: Thirteenth panel of table X R H
  Fourth character (Body Part) is value 4: Cervicothoracic Vertebral Joint
  Fifth character (Approach) is value 0: Open
  Sixth character (Device / Substance / Technology) is value G: Molybdenum Rhenium Alloy Spinal Stabilization Device
  Seventh character (Qualifier) is value B: New Technology Group 11

FY2027: Fourteenth panel of table X R H
  Fourth character (Body Part) is value 4: Cervicothoracic Vertebral Joint
  Fifth character (Approach) is value 0: Open
  Sixth character (Device / Substance / Technology) is value N: Carbon/PEEK Spinal Stabilization Device
  Seventh character (Qualifier) is value C: New Technology Group 12

FY2027: Fifteenth panel of table X R H
  Fourth character (Body Part) is value 4: Cervicothoracic Vertebral Joint
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value G: Molybdenum Rhenium Alloy Spinal Stabilization Device
  Seventh character (Qualifier) is value B: New Technology Group 11

FY2027: Sixteenth panel of table X R H
  Fourth character (Body Part) is value 4: Cervicothoracic Vertebral Joint
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value N: Carbon/PEEK Spinal Stabilization Device
  Seventh character (Qualifier) is value C: New Technology Group 12

FY2027: Seventeenth panel of table X R H
  Fourth character (Body Part) is value 4: Cervicothoracic Vertebral Joint
  Fifth character (Approach) is value 4: Percutaneous Endoscopic
  Sixth character (Device / Substance / Technology) is value G: Molybdenum Rhenium Alloy Spinal Stabilization Device
  Seventh character (Qualifier) is value B: New Technology Group 11

FY2027: Eighteenth panel of table X R H
  Fourth character (Body Part) is value 4: Cervicothoracic Vertebral Joint
  Fifth character (Approach) is value 4: Percutaneous Endoscopic
  Sixth character (Device / Substance / Technology) is value N: Carbon/PEEK Spinal Stabilization Device
  Seventh character (Qualifier) is value C: New Technology Group 12

No change: Nineteenth panel of table X R H
  Fourth character (Body Part) is value 6: Thoracic Vertebral Joint
  Fifth character (Approach) is value 0: Open
  Sixth character (Device / Substance / Technology) is value F: Carbon/PEEK Spinal Stabilization Device, Pedicle Based
  Seventh character (Qualifier) is value A: New Technology Group 10

No change: Twentieth panel of table X R H
  Fourth character (Body Part) is value 6: Thoracic Vertebral Joint
  Fifth character (Approach) is value 0: Open
  Sixth character (Device / Substance / Technology) is value G: Molybdenum Rhenium Alloy Spinal Stabilization Device
  Seventh character (Qualifier) is value B: New Technology Group 11

FY2027: Twenty-first panel of table X R H
  Fourth character (Body Part) is value 6: Thoracic Vertebral Joint
  Fifth character (Approach) is value 0: Open
  Sixth character (Device / Substance / Technology) is value N: Carbon/PEEK Spinal Stabilization Device
  Seventh character (Qualifier) is value C: New Technology Group 12

No change: Twenty-second panel of table X R H
  Fourth character (Body Part) is value 6: Thoracic Vertebral Joint
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value F: Carbon/PEEK Spinal Stabilization Device, Pedicle Based
  Seventh character (Qualifier) is value A: New Technology Group 10

No change: Twenty-third panel of table X R H
  Fourth character (Body Part) is value 6: Thoracic Vertebral Joint
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value G: Molybdenum Rhenium Alloy Spinal Stabilization Device
  Seventh character (Qualifier) is value B: New Technology Group 11

FY2027: Twenty-fourth panel of table X R H
  Fourth character (Body Part) is value 6: Thoracic Vertebral Joint
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value N: Carbon/PEEK Spinal Stabilization Device
  Seventh character (Qualifier) is value C: New Technology Group 12

No change: Twenty-fifth panel of table X R H
  Fourth character (Body Part) is value 6: Thoracic Vertebral Joint
  Fifth character (Approach) is value 4: Percutaneous Endoscopic
  Sixth character (Device / Substance / Technology) is value F: Carbon/PEEK Spinal Stabilization Device, Pedicle Based
  Seventh character (Qualifier) is value A: New Technology Group 10

No change: Twenty-sixth panel of table X R H
  Fourth character (Body Part) is value 6: Thoracic Vertebral Joint
  Fifth character (Approach) is value 4: Percutaneous Endoscopic
  Sixth character (Device / Substance / Technology) is value G: Molybdenum Rhenium Alloy Spinal Stabilization Device
  Seventh character (Qualifier) is value B: New Technology Group 11

FY2027: Twenty-seventh panel of table X R H
  Fourth character (Body Part) is value 6: Thoracic Vertebral Joint
  Fifth character (Approach) is value 4: Percutaneous Endoscopic
  Sixth character (Device / Substance / Technology) is value N: Carbon/PEEK Spinal Stabilization Device
  Seventh character (Qualifier) is value C: New Technology Group 12

No change: Twenty-eighth panel of table X R H
  Fourth character (Body Part) has 3 choices.
    First choice is value 7: Thoracic Vertebral Joints, 2 to 7
    Second choice is value 8: Thoracic Vertebral Joints, 8 or more
    Third choice is value A: Thoracolumbar Vertebral Joint
  Fifth character (Approach) has 3 choices.
    First choice is value 0: Open
    Second choice is value 3: Percutaneous
    Third choice is value 4: Percutaneous Endoscopic
  Sixth character (Device / Substance / Technology) is value F: Carbon/PEEK Spinal Stabilization Device, Pedicle Based
  Seventh character (Qualifier) is value A: New Technology Group 10

No change: Twenty-ninth panel of table X R H
  Fourth character (Body Part) is value B: Lumbar Vertebral Joint
  Fifth character (Approach) is value 0: Open
  Sixth character (Device / Substance / Technology) is value 1: Posterior Spinal Motion Preservation Device
  Seventh character (Qualifier) is value 8: New Technology Group 8

No change: Thirtieth panel of table X R H
  Fourth character (Body Part) has 2 choices.
    First choice is value B: Lumbar Vertebral Joint
    Second choice is value C: Lumbar Vertebral Joints, 2 or more
  Fifth character (Approach) has 3 choices.
    First choice is value 0: Open
    Second choice is value 3: Percutaneous
    Third choice is value 4: Percutaneous Endoscopic
  Sixth character (Device / Substance / Technology) is value F: Carbon/PEEK Spinal Stabilization Device, Pedicle Based
  Seventh character (Qualifier) is value A: New Technology Group 10

No change: Thirty-first panel of table X R H
  Fourth character (Body Part) is value D: Lumbosacral Joint
  Fifth character (Approach) is value 0: Open
  Sixth character (Device / Substance / Technology) is value 1: Posterior Spinal Motion Preservation Device
  Seventh character (Qualifier) is value 8: New Technology Group 8

No change: Thirty-second panel of table X R H
  Fourth character (Body Part) is value D: Lumbosacral Joint
  Fifth character (Approach) has 3 choices.
    First choice is value 0: Open
    Second choice is value 3: Percutaneous
    Third choice is value 4: Percutaneous Endoscopic
  Sixth character (Device / Substance / Technology) is value F: Carbon/PEEK Spinal Stabilization Device, Pedicle Based
  Seventh character (Qualifier) is value A: New Technology Group 10

No change: table X W 0
  First character (Section) is value X: New Technology
  Second character (Body System) is value W: Anatomical Regions
  Third character (Operation) is value 0: Introduction: Putting in or on a therapeutic, diagnostic, nutritional, physiological, or prophylactic substance except blood or blood products

No change: First panel of table X W 0
  Fourth character (Body Part) is value 1: Subcutaneous Tissue
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value 1: Daratumumab and Hyaluronidase-fihj
  Seventh character (Qualifier) is value 8: New Technology Group 8

No change: Second panel of table X W 0
  Fourth character (Body Part) is value 1: Subcutaneous Tissue
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value 2: Talquetamab Antineoplastic
  Seventh character (Qualifier) is value 9: New Technology Group 9

No change: Third panel of table X W 0
  Fourth character (Body Part) is value 1: Subcutaneous Tissue
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value 4: Teclistamab Antineoplastic
  Seventh character (Qualifier) is value 8: New Technology Group 8

FY2027: Fourth panel of table X W 0
  Fourth character (Body Part) is value 1: Subcutaneous Tissue
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value 4: Elamipretide
  Seventh character (Qualifier) is value C: New Technology Group 12

No change: Fifth panel of table X W 0
  Fourth character (Body Part) is value 1: Subcutaneous Tissue
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value 6: Dasiglucagon
  Seventh character (Qualifier) is value A: New Technology Group 10

No change: Sixth panel of table X W 0
  Fourth character (Body Part) is value 1: Subcutaneous Tissue
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value F: Other New Technology Therapeutic Substance
  Seventh character (Qualifier) is value 5: New Technology Group 5

No change: Seventh panel of table X W 0
  Fourth character (Body Part) is value 1: Subcutaneous Tissue
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) has 3 choices.
    First choice is value G: REGN-COV2 Monoclonal Antibody
    Second choice is value H: Other New Technology Monoclonal Antibody
    Third choice is value K: Leronlimab Monoclonal Antibody
  Seventh character (Qualifier) is value 6: New Technology Group 6

No change: Eighth panel of table X W 0
  Fourth character (Body Part) is value 1: Subcutaneous Tissue
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value L: Elranatamab Antineoplastic
  Seventh character (Qualifier) is value 9: New Technology Group 9

No change: Ninth panel of table X W 0
  Fourth character (Body Part) is value 1: Subcutaneous Tissue
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value S: COVID-19 Vaccine Dose 1
  Seventh character (Qualifier) is value 6: New Technology Group 6

No change: Tenth panel of table X W 0
  Fourth character (Body Part) is value 1: Subcutaneous Tissue
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value S: Epcoritamab Monoclonal Antibody
  Seventh character (Qualifier) is value 9: New Technology Group 9

No change: Eleventh panel of table X W 0
  Fourth character (Body Part) is value 1: Subcutaneous Tissue
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value T: COVID-19 Vaccine Dose 2
  Seventh character (Qualifier) is value 6: New Technology Group 6

No change: Twelfth panel of table X W 0
  Fourth character (Body Part) is value 1: Subcutaneous Tissue
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value T: Rozanolixizumab-noli Monoclonal Antibody
  Seventh character (Qualifier) is value B: New Technology Group 11

No change: Thirteenth panel of table X W 0
  Fourth character (Body Part) is value 1: Subcutaneous Tissue
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value U: COVID-19 Vaccine
  Seventh character (Qualifier) is value 6: New Technology Group 6

No change: Fourteenth panel of table X W 0
  Fourth character (Body Part) is value 1: Subcutaneous Tissue
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value V: COVID-19 Vaccine Dose 3
  Seventh character (Qualifier) is value 7: New Technology Group 7

No change: Fifteenth panel of table X W 0
  Fourth character (Body Part) is value 1: Subcutaneous Tissue
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value W: Caplacizumab
  Seventh character (Qualifier) is value 5: New Technology Group 5

No change: Sixteenth panel of table X W 0
  Fourth character (Body Part) is value 1: Subcutaneous Tissue
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value W: COVID-19 Vaccine Booster
  Seventh character (Qualifier) is value 7: New Technology Group 7

No change: Seventeenth panel of table X W 0
  Fourth character (Body Part) is value 2: Muscle
  Fifth character (Approach) is value 0: Open
  Sixth character (Device / Substance / Technology) is value D: Engineered Allogeneic Thymus Tissue
  Seventh character (Qualifier) is value 8: New Technology Group 8

No change: Eighteenth panel of table X W 0
  Fourth character (Body Part) is value 2: Muscle
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) has 3 choices.
    First choice is value S: COVID-19 Vaccine Dose 1
    Second choice is value T: COVID-19 Vaccine Dose 2
    Third choice is value U: COVID-19 Vaccine
  Seventh character (Qualifier) is value 6: New Technology Group 6

No change: Nineteenth panel of table X W 0
  Fourth character (Body Part) is value 2: Muscle
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) has 3 choices.
    First choice is value V: COVID-19 Vaccine Dose 3
    Second choice is value W: COVID-19 Vaccine Booster
    Third choice is value Y: Other New Technology Monoclonal Antibody
  Seventh character (Qualifier) is value 7: New Technology Group 7

No change: Twentieth panel of table X W 0
  Fourth character (Body Part) is value 3: Peripheral Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value 0: Spesolimab Monoclonal Antibody
  Seventh character (Qualifier) is value 8: New Technology Group 8

No change: Twenty-first panel of table X W 0
  Fourth character (Body Part) is value 3: Peripheral Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) has 2 choices.
    First choice is value 0: Alpha1-proteinase Inhibitor
    Second choice is value 1: Anitocabtagene Autoleucel Immunotherapy
  Seventh character (Qualifier) is value B: New Technology Group 11

No change: Twenty-second panel of table X W 0
  Fourth character (Body Part) is value 3: Peripheral Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) has 2 choices.
    First choice is value 3: Bentracimab, Ticagrelor Reversal Agent
    Second choice is value 4: Cefepime-taniborbactam Anti-infective
  Seventh character (Qualifier) is value A: New Technology Group 10

No change: Twenty-third panel of table X W 0
  Fourth character (Body Part) is value 3: Peripheral Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value 5: Narsoplimab Monoclonal Antibody
  Seventh character (Qualifier) is value 7: New Technology Group 7

No change: Twenty-fourth panel of table X W 0
  Fourth character (Body Part) is value 3: Peripheral Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value 5: Mosunetuzumab Antineoplastic
  Seventh character (Qualifier) is value 8: New Technology Group 8

No change: Twenty-fifth panel of table X W 0
  Fourth character (Body Part) is value 3: Peripheral Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value 5: Ceftobiprole Medocaril Anti-infective
  Seventh character (Qualifier) is value A: New Technology Group 10

No change: Twenty-sixth panel of table X W 0
  Fourth character (Body Part) is value 3: Peripheral Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value 6: Afamitresgene Autoleucel Immunotherapy
  Seventh character (Qualifier) is value 8: New Technology Group 8

FY2027: Twenty-seventh panel of table X W 0
  Fourth character (Body Part) is value 3: Peripheral Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value 6: Landiolol Antiarrhythmic
  Seventh character (Qualifier) is value C: New Technology Group 12

No change: Twenty-eighth panel of table X W 0
  Fourth character (Body Part) is value 3: Peripheral Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value 7: Coagulation Factor Xa, Inactivated
  Seventh character (Qualifier) is value 2: New Technology Group 2

No change: Twenty-ninth panel of table X W 0
  Fourth character (Body Part) is value 3: Peripheral Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value 7: Tabelecleucel Immunotherapy
  Seventh character (Qualifier) is value 8: New Technology Group 8

FY2027: Thirtieth panel of table X W 0
  Fourth character (Body Part) is value 3: Peripheral Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value 7: Zimislecel Allogeneic Stem Cell-Derived Islet Cell Therapy
  Seventh character (Qualifier) is value C: New Technology Group 12

No change: Thirty-first panel of table X W 0
  Fourth character (Body Part) is value 3: Peripheral Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value 8: Treosulfan
  Seventh character (Qualifier) is value 8: New Technology Group 8

No change: Thirty-second panel of table X W 0
  Fourth character (Body Part) is value 3: Peripheral Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value 8: Obecabtagene Autoleucel
  Seventh character (Qualifier) is value A: New Technology Group 10

No change: Thirty-third panel of table X W 0
  Fourth character (Body Part) is value 3: Peripheral Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value 9: Ceftolozane/Tazobactam Anti-infective
  Seventh character (Qualifier) is value 6: New Technology Group 6

No change: Thirty-fourth panel of table X W 0
  Fourth character (Body Part) is value 3: Peripheral Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value 9: Inebilizumab-cdon
  Seventh character (Qualifier) is value 8: New Technology Group 8

No change: Thirty-fifth panel of table X W 0
  Fourth character (Body Part) is value 3: Peripheral Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value 9: Odronextamab Antineoplastic
  Seventh character (Qualifier) is value A: New Technology Group 10

No change: Thirty-sixth panel of table X W 0
  Fourth character (Body Part) is value 3: Peripheral Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value A: Ciltacabtagene Autoleucel
  Seventh character (Qualifier) is value 7: New Technology Group 7

No change: Thirty-seventh panel of table X W 0
  Fourth character (Body Part) is value 3: Peripheral Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value B: Cytarabine and Daunorubicin Liposome Antineoplastic
  Seventh character (Qualifier) is value 3: New Technology Group 3

No change: Thirty-eighth panel of table X W 0
  Fourth character (Body Part) is value 3: Peripheral Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value B: Orca-T Allogeneic T-cell Immunotherapy
  Seventh character (Qualifier) is value A: New Technology Group 10

No change: Thirty-ninth panel of table X W 0
  Fourth character (Body Part) is value 3: Peripheral Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value C: Engineered Chimeric Antigen Receptor T-cell Immunotherapy, Autologous
  Seventh character (Qualifier) is value 7: New Technology Group 7

No change: Fortieth panel of table X W 0
  Fourth character (Body Part) is value 3: Peripheral Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) has 2 choices.
    First choice is value C: Zanidatamab Antineoplastic
    Second choice is value D: Donislecel-jujn Allogeneic Pancreatic Islet Cellular Suspension
  Seventh character (Qualifier) is value A: New Technology Group 10

No change: Forty-first panel of table X W 0
  Fourth character (Body Part) is value 3: Peripheral Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value E: Remdesivir Anti-infective
  Seventh character (Qualifier) is value 5: New Technology Group 5

No change: Forty-second panel of table X W 0
  Fourth character (Body Part) is value 3: Peripheral Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value F: Other New Technology Therapeutic Substance
  Seventh character (Qualifier) is value 3: New Technology Group 3

No change: Forty-third panel of table X W 0
  Fourth character (Body Part) is value 3: Peripheral Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value F: Other New Technology Therapeutic Substance
  Seventh character (Qualifier) is value 5: New Technology Group 5

No change: Forty-fourth panel of table X W 0
  Fourth character (Body Part) is value 3: Peripheral Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value F: Non-Chimeric Antigen Receptor T-cell Immune Effector Cell Therapy
  Seventh character (Qualifier) is value A: New Technology Group 10

No change: Forty-fifth panel of table X W 0
  Fourth character (Body Part) is value 3: Peripheral Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value F: Valoctocogene Roxaparvovec-rvox
  Seventh character (Qualifier) is value B: New Technology Group 11

No change: Forty-sixth panel of table X W 0
  Fourth character (Body Part) is value 3: Peripheral Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value G: Sarilumab
  Seventh character (Qualifier) is value 5: New Technology Group 5

No change: Forty-seventh panel of table X W 0
  Fourth character (Body Part) is value 3: Peripheral Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value G: REGN-COV2 Monoclonal Antibody
  Seventh character (Qualifier) is value 6: New Technology Group 6

No change: Forty-eighth panel of table X W 0
  Fourth character (Body Part) is value 3: Peripheral Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value G: Engineered Chimeric Antigen Receptor T-cell Immunotherapy, Allogeneic
  Seventh character (Qualifier) is value 7: New Technology Group 7

No change: Forty-ninth panel of table X W 0
  Fourth character (Body Part) is value 3: Peripheral Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value H: Tocilizumab
  Seventh character (Qualifier) is value 5: New Technology Group 5

No change: Fiftieth panel of table X W 0
  Fourth character (Body Part) is value 3: Peripheral Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value H: Other New Technology Monoclonal Antibody
  Seventh character (Qualifier) is value 6: New Technology Group 6

No change: Fifty-first panel of table X W 0
  Fourth character (Body Part) is value 3: Peripheral Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) has 3 choices.
    First choice is value H: Axicabtagene Ciloleucel Immunotherapy
    Second choice is value J: Tisagenlecleucel Immunotherapy
    Third choice is value K: Idecabtagene Vicleucel Immunotherapy
  Seventh character (Qualifier) is value 7: New Technology Group 7

No change: Fifty-second panel of table X W 0
  Fourth character (Body Part) is value 3: Peripheral Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value K: Sulbactam-Durlobactam
  Seventh character (Qualifier) is value 9: New Technology Group 9

No change: Fifty-third panel of table X W 0
  Fourth character (Body Part) is value 3: Peripheral Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value L: CD24Fc Immunomodulator
  Seventh character (Qualifier) is value 6: New Technology Group 6

No change: Fifty-fourth panel of table X W 0
  Fourth character (Body Part) is value 3: Peripheral Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) has 2 choices.
    First choice is value L: Lifileucel Immunotherapy
    Second choice is value M: Brexucabtagene Autoleucel Immunotherapy
  Seventh character (Qualifier) is value 7: New Technology Group 7

No change: Fifty-fifth panel of table X W 0
  Fourth character (Body Part) is value 3: Peripheral Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value M: Emapalumab-lzsg Anti-IFNy Monoclonal Antibody
  Seventh character (Qualifier) is value A: New Technology Group 10

No change: Fifty-sixth panel of table X W 0
  Fourth character (Body Part) is value 3: Peripheral Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value N: Lisocabtagene Maraleucel Immunotherapy
  Seventh character (Qualifier) is value 7: New Technology Group 7

No change: Fifty-seventh panel of table X W 0
  Fourth character (Body Part) is value 3: Peripheral Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value N: Tarlatamab-dlle Antineoplastic
  Seventh character (Qualifier) is value A: New Technology Group 10

No change: Fifty-eighth panel of table X W 0
  Fourth character (Body Part) is value 3: Peripheral Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value P: Glofitamab Antineoplastic
  Seventh character (Qualifier) is value 9: New Technology Group 9

No change: Fifty-ninth panel of table X W 0
  Fourth character (Body Part) is value 3: Peripheral Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value P: Aztreonam-avibactam Anti-infective
  Seventh character (Qualifier) is value B: New Technology Group 11

No change: Sixtieth panel of table X W 0
  Fourth character (Body Part) is value 3: Peripheral Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value Q: Tagraxofusp-erzs Antineoplastic
  Seventh character (Qualifier) is value 5: New Technology Group 5

No change: Sixty-first panel of table X W 0
  Fourth character (Body Part) is value 3: Peripheral Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value Q: Posoleucel
  Seventh character (Qualifier) is value 9: New Technology Group 9

No change: Sixty-second panel of table X W 0
  Fourth character (Body Part) is value 3: Peripheral Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value Q: Iloprost
  Seventh character (Qualifier) is value B: New Technology Group 11

No change: Sixty-third panel of table X W 0
  Fourth character (Body Part) is value 3: Peripheral Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value R: Rezafungin
  Seventh character (Qualifier) is value 9: New Technology Group 9

No change: Sixty-fourth panel of table X W 0
  Fourth character (Body Part) is value 3: Peripheral Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value R: Letetresgene Autoleucel
  Seventh character (Qualifier) is value B: New Technology Group 11

No change: Sixty-fifth panel of table X W 0
  Fourth character (Body Part) is value 3: Peripheral Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) has 2 choices.
    First choice is value S: Iobenguane I-131 Antineoplastic
    Second choice is value W: Caplacizumab
  Seventh character (Qualifier) is value 5: New Technology Group 5

No change: Sixty-sixth panel of table X W 0
  Fourth character (Body Part) is value 3: Peripheral Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value W: Fosfomycin Anti-infective
  Seventh character (Qualifier) is value B: New Technology Group 11

No change: Sixty-seventh panel of table X W 0
  Fourth character (Body Part) is value 4: Central Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value 0: Spesolimab Monoclonal Antibody
  Seventh character (Qualifier) is value 8: New Technology Group 8

No change: Sixty-eighth panel of table X W 0
  Fourth character (Body Part) is value 4: Central Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) has 2 choices.
    First choice is value 0: Alpha1-proteinase Inhibitor
    Second choice is value 1: Anitocabtagene Autoleucel Immunotherapy
  Seventh character (Qualifier) is value B: New Technology Group 11

No change: Sixty-ninth panel of table X W 0
  Fourth character (Body Part) is value 4: Central Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) has 2 choices.
    First choice is value 3: Bentracimab, Ticagrelor Reversal Agent
    Second choice is value 4: Cefepime-taniborbactam Anti-infective
  Seventh character (Qualifier) is value A: New Technology Group 10

No change: Seventieth panel of table X W 0
  Fourth character (Body Part) is value 4: Central Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value 5: Narsoplimab Monoclonal Antibody
  Seventh character (Qualifier) is value 7: New Technology Group 7

No change: Seventy-first panel of table X W 0
  Fourth character (Body Part) is value 4: Central Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value 5: Mosunetuzumab Antineoplastic
  Seventh character (Qualifier) is value 8: New Technology Group 8

No change: Seventy-second panel of table X W 0
  Fourth character (Body Part) is value 4: Central Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value 5: Ceftobiprole Medocaril Anti-infective
  Seventh character (Qualifier) is value A: New Technology Group 10

No change: Seventy-third panel of table X W 0
  Fourth character (Body Part) is value 4: Central Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value 6: Afamitresgene Autoleucel Immunotherapy
  Seventh character (Qualifier) is value 8: New Technology Group 8

FY2027: Seventy-fourth panel of table X W 0
  Fourth character (Body Part) is value 4: Central Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value 6: Landiolol Antiarrhythmic
  Seventh character (Qualifier) is value C: New Technology Group 12

No change: Seventy-fifth panel of table X W 0
  Fourth character (Body Part) is value 4: Central Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value 7: Coagulation Factor Xa, Inactivated
  Seventh character (Qualifier) is value 2: New Technology Group 2

No change: Seventy-sixth panel of table X W 0
  Fourth character (Body Part) is value 4: Central Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) has 2 choices.
    First choice is value 7: Tabelecleucel Immunotherapy
    Second choice is value 8: Treosulfan
  Seventh character (Qualifier) is value 8: New Technology Group 8

No change: Seventy-seventh panel of table X W 0
  Fourth character (Body Part) is value 4: Central Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value 8: Obecabtagene Autoleucel
  Seventh character (Qualifier) is value A: New Technology Group 10

No change: Seventy-eighth panel of table X W 0
  Fourth character (Body Part) is value 4: Central Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value 9: Ceftolozane/Tazobactam Anti-infective
  Seventh character (Qualifier) is value 6: New Technology Group 6

No change: Seventy-ninth panel of table X W 0
  Fourth character (Body Part) is value 4: Central Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value 9: Inebilizumab-cdon
  Seventh character (Qualifier) is value 8: New Technology Group 8

No change: Eightieth panel of table X W 0
  Fourth character (Body Part) is value 4: Central Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value 9: Odronextamab Antineoplastic
  Seventh character (Qualifier) is value A: New Technology Group 10

No change: Eighty-first panel of table X W 0
  Fourth character (Body Part) is value 4: Central Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value A: Ciltacabtagene Autoleucel
  Seventh character (Qualifier) is value 7: New Technology Group 7

No change: Eighty-second panel of table X W 0
  Fourth character (Body Part) is value 4: Central Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value B: Cytarabine and Daunorubicin Liposome Antineoplastic
  Seventh character (Qualifier) is value 3: New Technology Group 3

No change: Eighty-third panel of table X W 0
  Fourth character (Body Part) is value 4: Central Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value B: Orca-T Allogeneic T-cell Immunotherapy
  Seventh character (Qualifier) is value A: New Technology Group 10

No change: Eighty-fourth panel of table X W 0
  Fourth character (Body Part) is value 4: Central Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value C: Engineered Chimeric Antigen Receptor T-cell Immunotherapy, Autologous
  Seventh character (Qualifier) is value 7: New Technology Group 7

No change: Eighty-fifth panel of table X W 0
  Fourth character (Body Part) is value 4: Central Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value C: Zanidatamab Antineoplastic
  Seventh character (Qualifier) is value A: New Technology Group 10

No change: Eighty-sixth panel of table X W 0
  Fourth character (Body Part) is value 4: Central Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value E: Remdesivir Anti-infective
  Seventh character (Qualifier) is value 5: New Technology Group 5

No change: Eighty-seventh panel of table X W 0
  Fourth character (Body Part) is value 4: Central Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value F: Other New Technology Therapeutic Substance
  Seventh character (Qualifier) is value 3: New Technology Group 3

No change: Eighty-eighth panel of table X W 0
  Fourth character (Body Part) is value 4: Central Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value F: Other New Technology Therapeutic Substance
  Seventh character (Qualifier) is value 5: New Technology Group 5

No change: Eighty-ninth panel of table X W 0
  Fourth character (Body Part) is value 4: Central Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value F: Non-Chimeric Antigen Receptor T-cell Immune Effector Cell Therapy
  Seventh character (Qualifier) is value A: New Technology Group 10

No change: Ninetieth panel of table X W 0
  Fourth character (Body Part) is value 4: Central Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value F: Valoctocogene Roxaparvovec-rvox
  Seventh character (Qualifier) is value B: New Technology Group 11

No change: Ninety-first panel of table X W 0
  Fourth character (Body Part) is value 4: Central Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value G: Sarilumab
  Seventh character (Qualifier) is value 5: New Technology Group 5

No change: Ninety-second panel of table X W 0
  Fourth character (Body Part) is value 4: Central Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value G: REGN-COV2 Monoclonal Antibody
  Seventh character (Qualifier) is value 6: New Technology Group 6

No change: Ninety-third panel of table X W 0
  Fourth character (Body Part) is value 4: Central Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value G: Engineered Chimeric Antigen Receptor T-cell Immunotherapy, Allogeneic
  Seventh character (Qualifier) is value 7: New Technology Group 7

No change: Ninety-fourth panel of table X W 0
  Fourth character (Body Part) is value 4: Central Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value H: Tocilizumab
  Seventh character (Qualifier) is value 5: New Technology Group 5

No change: Ninety-fifth panel of table X W 0
  Fourth character (Body Part) is value 4: Central Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value H: Other New Technology Monoclonal Antibody
  Seventh character (Qualifier) is value 6: New Technology Group 6

No change: Ninety-sixth panel of table X W 0
  Fourth character (Body Part) is value 4: Central Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) has 3 choices.
    First choice is value H: Axicabtagene Ciloleucel Immunotherapy
    Second choice is value J: Tisagenlecleucel Immunotherapy
    Third choice is value K: Idecabtagene Vicleucel Immunotherapy
  Seventh character (Qualifier) is value 7: New Technology Group 7

No change: Ninety-seventh panel of table X W 0
  Fourth character (Body Part) is value 4: Central Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value K: Sulbactam-Durlobactam
  Seventh character (Qualifier) is value 9: New Technology Group 9

No change: Ninety-eighth panel of table X W 0
  Fourth character (Body Part) is value 4: Central Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value L: CD24Fc Immunomodulator
  Seventh character (Qualifier) is value 6: New Technology Group 6

No change: Ninety-ninth panel of table X W 0
  Fourth character (Body Part) is value 4: Central Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) has 2 choices.
    First choice is value L: Lifileucel Immunotherapy
    Second choice is value M: Brexucabtagene Autoleucel Immunotherapy
  Seventh character (Qualifier) is value 7: New Technology Group 7

No change: One hundredth panel of table X W 0
  Fourth character (Body Part) is value 4: Central Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value M: Emapalumab-lzsg Anti-IFNy Monoclonal Antibody
  Seventh character (Qualifier) is value A: New Technology Group 10

No change: One hundred First panel of table X W 0
  Fourth character (Body Part) is value 4: Central Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value N: Lisocabtagene Maraleucel Immunotherapy
  Seventh character (Qualifier) is value 7: New Technology Group 7

No change: One hundred Second panel of table X W 0
  Fourth character (Body Part) is value 4: Central Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value N: Tarlatamab-dlle Antineoplastic
  Seventh character (Qualifier) is value A: New Technology Group 10

No change: One hundred Third panel of table X W 0
  Fourth character (Body Part) is value 4: Central Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value P: Glofitamab Antineoplastic
  Seventh character (Qualifier) is value 9: New Technology Group 9

No change: One hundred Fourth panel of table X W 0
  Fourth character (Body Part) is value 4: Central Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value P: Aztreonam-avibactam Anti-infective
  Seventh character (Qualifier) is value B: New Technology Group 11

No change: One hundred Fifth panel of table X W 0
  Fourth character (Body Part) is value 4: Central Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value Q: Tagraxofusp-erzs Antineoplastic
  Seventh character (Qualifier) is value 5: New Technology Group 5

No change: One hundred Sixth panel of table X W 0
  Fourth character (Body Part) is value 4: Central Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value Q: Posoleucel
  Seventh character (Qualifier) is value 9: New Technology Group 9

No change: One hundred Seventh panel of table X W 0
  Fourth character (Body Part) is value 4: Central Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value Q: Iloprost
  Seventh character (Qualifier) is value B: New Technology Group 11

No change: One hundred Eighth panel of table X W 0
  Fourth character (Body Part) is value 4: Central Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value R: Rezafungin
  Seventh character (Qualifier) is value 9: New Technology Group 9

No change: One hundred Ninth panel of table X W 0
  Fourth character (Body Part) is value 4: Central Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value R: Letetresgene Autoleucel
  Seventh character (Qualifier) is value B: New Technology Group 11

No change: One hundred Tenth panel of table X W 0
  Fourth character (Body Part) is value 4: Central Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) has 2 choices.
    First choice is value S: Iobenguane I-131 Antineoplastic
    Second choice is value W: Caplacizumab
  Seventh character (Qualifier) is value 5: New Technology Group 5

No change: One hundred Eleventh panel of table X W 0
  Fourth character (Body Part) is value 4: Central Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value W: Fosfomycin Anti-infective
  Seventh character (Qualifier) is value B: New Technology Group 11

No change: One hundred Twelfth panel of table X W 0
  Fourth character (Body Part) is value 5: Peripheral Artery
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value 4: Stem Cells, Somatic
  Seventh character (Qualifier) is value B: New Technology Group 11

No change: One hundred Thirteenth panel of table X W 0
  Fourth character (Body Part) is value 5: Peripheral Artery
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value T: Melphalan Hydrochloride Antineoplastic
  Seventh character (Qualifier) is value 9: New Technology Group 9

No change: One hundred Fourteenth panel of table X W 0
  Fourth character (Body Part) is value 6: Cerebral Ventricle
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value 2: CPI-601 Enzyme Replacement Therapy
  Seventh character (Qualifier) is value B: New Technology Group 11

No change: One hundred Fifteenth panel of table X W 0
  Fourth character (Body Part) is value D: Mouth and Pharynx
  Fifth character (Approach) is value X: External
  Sixth character (Device / Substance / Technology) is value 3: Maribavir Anti-infective
  Seventh character (Qualifier) is value 8: New Technology Group 8

No change: One hundred Sixteenth panel of table X W 0
  Fourth character (Body Part) is value D: Mouth and Pharynx
  Fifth character (Approach) is value X: External
  Sixth character (Device / Substance / Technology) is value 8: Uridine Triacetate
  Seventh character (Qualifier) is value 2: New Technology Group 2

No change: One hundred Seventeenth panel of table X W 0
  Fourth character (Body Part) is value D: Mouth and Pharynx
  Fifth character (Approach) is value X: External
  Sixth character (Device / Substance / Technology) is value F: Other New Technology Therapeutic Substance
  Seventh character (Qualifier) is value 5: New Technology Group 5

No change: One hundred Eighteenth panel of table X W 0
  Fourth character (Body Part) is value D: Mouth and Pharynx
  Fifth character (Approach) is value X: External
  Sixth character (Device / Substance / Technology) is value J: Quizartinib Antineoplastic
  Seventh character (Qualifier) is value 9: New Technology Group 9

No change: One hundred Nineteenth panel of table X W 0
  Fourth character (Body Part) is value D: Mouth and Pharynx
  Fifth character (Approach) is value X: External
  Sixth character (Device / Substance / Technology) is value K: Sabizabulin
  Seventh character (Qualifier) is value 8: New Technology Group 8

No change: One hundred Twentieth panel of table X W 0
  Fourth character (Body Part) is value D: Mouth and Pharynx
  Fifth character (Approach) is value X: External
  Sixth character (Device / Substance / Technology) is value M: Baricitinib
  Seventh character (Qualifier) is value 6: New Technology Group 6

No change: One hundred Twenty-first panel of table X W 0
  Fourth character (Body Part) is value D: Mouth and Pharynx
  Fifth character (Approach) is value X: External
  Sixth character (Device / Substance / Technology) is value N: SER-109
  Seventh character (Qualifier) is value 9: New Technology Group 9

No change: One hundred Twenty-second panel of table X W 0
  Fourth character (Body Part) is value D: Mouth and Pharynx
  Fifth character (Approach) is value X: External
  Sixth character (Device / Substance / Technology) is value V: Xanomeline and Trospium Chloride
  Seventh character (Qualifier) is value B: New Technology Group 11

Revise from: One hundred Twenty-third panel of table X W 0
  Fourth character (Body Part) is value E: Ear(s)
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value 3: DB-OTO via Intracochlear Infusion
  Seventh character (Qualifier) is value B: New Technology Group 11

Revise to: One hundred Twenty-third panel of table X W 0
  Fourth character (Body Part) is value E: Ear(s)
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value 3: Lunsotogene Parvec-cwha via Intracochlear Infusion
  Seventh character (Qualifier) is value B: New Technology Group 11

No change: One hundred Twenty-fourth panel of table X W 0
  Fourth character (Body Part) is value G: Upper GI
  Fifth character (Approach) is value 7: Via Natural or Artificial Opening
  Sixth character (Device / Substance / Technology) has 2 choices.
    First choice is value 3: Maribavir Anti-infective
    Second choice is value K: Sabizabulin
  Seventh character (Qualifier) is value 8: New Technology Group 8

No change: One hundred Twenty-fifth panel of table X W 0
  Fourth character (Body Part) is value G: Upper GI
  Fifth character (Approach) is value 7: Via Natural or Artificial Opening
  Sixth character (Device / Substance / Technology) is value M: Baricitinib
  Seventh character (Qualifier) is value 6: New Technology Group 6

No change: One hundred Twenty-sixth panel of table X W 0
  Fourth character (Body Part) is value G: Upper GI
  Fifth character (Approach) is value 8: Via Natural or Artificial Opening Endoscopic
  Sixth character (Device / Substance / Technology) is value 8: Mineral-based Topical Hemostatic Agent
  Seventh character (Qualifier) is value 6: New Technology Group 6

No change: One hundred Twenty-seventh panel of table X W 0
  Fourth character (Body Part) is value H: Lower GI
  Fifth character (Approach) is value 7: Via Natural or Artificial Opening
  Sixth character (Device / Substance / Technology) has 2 choices.
    First choice is value 3: Maribavir Anti-infective
    Second choice is value K: Sabizabulin
  Seventh character (Qualifier) is value 8: New Technology Group 8

No change: One hundred Twenty-eighth panel of table X W 0
  Fourth character (Body Part) is value H: Lower GI
  Fifth character (Approach) is value 7: Via Natural or Artificial Opening
  Sixth character (Device / Substance / Technology) is value M: Baricitinib
  Seventh character (Qualifier) is value 6: New Technology Group 6

No change: One hundred Twenty-ninth panel of table X W 0
  Fourth character (Body Part) is value H: Lower GI
  Fifth character (Approach) is value 7: Via Natural or Artificial Opening
  Sixth character (Device / Substance / Technology) is value X: Broad Consortium Microbiota-based Live Biotherapeutic Suspension
  Seventh character (Qualifier) is value 8: New Technology Group 8

No change: One hundred Thirtieth panel of table X W 0
  Fourth character (Body Part) is value H: Lower GI
  Fifth character (Approach) is value 8: Via Natural or Artificial Opening Endoscopic
  Sixth character (Device / Substance / Technology) is value 8: Mineral-based Topical Hemostatic Agent
  Seventh character (Qualifier) is value 6: New Technology Group 6

No change: One hundred Thirty-first panel of table X W 0
  Fourth character (Body Part) has 4 choices.
    First choice is value J: Coronary Artery, One Artery
    Second choice is value K: Coronary Artery, Two Arteries
    Third choice is value L: Coronary Artery, Three Arteries
    Fourth choice is value M: Coronary Artery, Four or More Arteries
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) has 4 choices.
    First choice is value H: Paclitaxel-Coated Balloon Technology, One Balloon
    Second choice is value J: Paclitaxel-Coated Balloon Technology, Two Balloons
    Third choice is value K: Paclitaxel-Coated Balloon Technology, Three Balloons
    Fourth choice is value L: Paclitaxel-Coated Balloon Technology, Four or More Balloons
  Seventh character (Qualifier) is value A: New Technology Group 10

No change: One hundred Thirty-second panel of table X W 0
  Fourth character (Body Part) is value Q: Cranial Cavity and Brain
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value 1: Eladocagene exuparvovec
  Seventh character (Qualifier) is value 6: New Technology Group 6

FY2027: One hundred Thirty-third panel of table X W 0
  Fourth character (Body Part) is value Q: Cranial Cavity and Brain
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value 5: Ifezuntirgene Inilparvovec
  Seventh character (Qualifier) is value C: New Technology Group 12

FY2027: One hundred Thirty-fourth panel of table X W 0
  Fourth character (Body Part) is value U: Joints
  Fifth character (Approach) is value 0: Open
  Sixth character (Device / Substance / Technology) is value C: Recombinant Human Bone Morphogenetic Protein-2 with Collagen Scaffold
  Seventh character (Qualifier) is value C: New Technology Group 12

No change: One hundred Thirty-fifth panel of table X W 0
  Fourth character (Body Part) is value U: Joints
  Fifth character (Approach) is value 0: Open
  Sixth character (Device / Substance / Technology) is value G: Vancomycin Hydrochloride and Tobramycin Sulfate Anti-Infective, Temporary Irrigation Spacer System
  Seventh character (Qualifier) is value A: New Technology Group 10

No change: One hundred Thirty-sixth panel of table X W 0
  Fourth character (Body Part) is value U: Joints
  Fifth character (Approach) has 3 choices.
    First choice is value 0: Open
    Second choice is value 3: Percutaneous
    Third choice is value 4: Percutaneous Endoscopic
  Sixth character (Device / Substance / Technology) is value X: Peptide Enhanced Bone Void Filler
  Seventh character (Qualifier) is value B: New Technology Group 11

FY2027: One hundred Thirty-seventh panel of table X W 0
  Fourth character (Body Part) is value V: Bones
  Fifth character (Approach) is value 0: Open
  Sixth character (Device / Substance / Technology) is value B: Vancomycin-eluting Bone Void Filler
  Seventh character (Qualifier) is value C: New Technology Group 12

Revise from: One hundred Thirty-eighth panel of table X W 0
  Fourth character (Body Part) is value V: Bones
  Fifth character (Approach) is value 0: Open
  Sixth character (Device / Substance / Technology) is value P: Antibiotic-eluting Bone Void Filler
  Seventh character (Qualifier) is value 7: New Technology Group 7

Revise to: One hundred Thirty-eighth panel of table X W 0
  Fourth character (Body Part) is value V: Bones
  Fifth character (Approach) is value 0: Open
  Sixth character (Device / Substance / Technology) is value P: Gentamicin-eluting Bone Void Filler
  Seventh character (Qualifier) is value 7: New Technology Group 7

No change: One hundred Thirty-ninth panel of table X W 0
  Fourth character (Body Part) is value V: Bones
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value W: AGN1 Bone Void Filler
  Seventh character (Qualifier) is value A: New Technology Group 10

No change: table X W 1
  First character (Section) is value X: New Technology
  Second character (Body System) is value W: Anatomical Regions
  Third character (Operation) is value 1: Transfusion: Putting in blood or blood products

No change: First panel of table X W 1
  Fourth character (Body Part) is value 3: Peripheral Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value 2: Plasma, Convalescent (Nonautologous)
  Seventh character (Qualifier) is value 5: New Technology Group 5

No change: Second panel of table X W 1
  Fourth character (Body Part) is value 3: Peripheral Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value 7: Marnetegragene Autotemcel
  Seventh character (Qualifier) is value A: New Technology Group 10

No change: Third panel of table X W 1
  Fourth character (Body Part) is value 3: Peripheral Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) has 2 choices.
    First choice is value B: Betibeglogene Autotemcel
    Second choice is value C: Omidubicel
  Seventh character (Qualifier) is value 8: New Technology Group 8

FY2027: Fourth panel of table X W 1
  Fourth character (Body Part) is value 3: Peripheral Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value E: Hyperimmune Globulin
  Seventh character (Qualifier) is value 7: New Technology Group 7

FY2027: Fifth panel of table X W 1
  Fourth character (Body Part) is value 3: Peripheral Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value G: Atidarsagene Autotemcel
  Seventh character (Qualifier) is value 8: New Technology Group 8

No change: Sixth panel of table X W 1
  Fourth character (Body Part) is value 3: Peripheral Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value H: Lovotibeglogene Autotemcel
  Seventh character (Qualifier) is value 9: New Technology Group 9

No change: Seventh panel of table X W 1
  Fourth character (Body Part) is value 3: Peripheral Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value J: Exagamglogene Autotemcel
  Seventh character (Qualifier) is value 8: New Technology Group 8

No change: Eighth panel of table X W 1
  Fourth character (Body Part) is value 3: Peripheral Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) has 2 choices.
    First choice is value S: Mozafancogene Autotemcel
    Second choice is value Y: Nonautologous (Human) Fibrinogen Concentrate, Shelf-stable
  Seventh character (Qualifier) is value B: New Technology Group 11

No change: Ninth panel of table X W 1
  Fourth character (Body Part) is value 4: Central Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value 2: Plasma, Convalescent (Nonautologous)
  Seventh character (Qualifier) is value 5: New Technology Group 5

No change: Tenth panel of table X W 1
  Fourth character (Body Part) is value 4: Central Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value 7: Marnetegragene Autotemcel
  Seventh character (Qualifier) is value A: New Technology Group 10

No change: Eleventh panel of table X W 1
  Fourth character (Body Part) is value 4: Central Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) has 2 choices.
    First choice is value B: Betibeglogene Autotemcel
    Second choice is value C: Omidubicel
  Seventh character (Qualifier) is value 8: New Technology Group 8

FY2027: Twelfth panel of table X W 1
  Fourth character (Body Part) is value 4: Central Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value E: Hyperimmune Globulin
  Seventh character (Qualifier) is value 7: New Technology Group 7

Revise from: Thirteenth panel of table X W 1
  Fourth character (Body Part) is value 4: Central Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) has 2 choices.
    First choice is value F: OTL-103
    Second choice is value G: Atidarsagene Autotemcel
  Seventh character (Qualifier) is value 8: New Technology Group 8

Revise to: Thirteenth panel of table X W 1
  Fourth character (Body Part) is value 4: Central Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) has 2 choices.
    First choice is value F: Etuvetidigene Autotemcel
    Second choice is value G: Atidarsagene Autotemcel
  Seventh character (Qualifier) is value 8: New Technology Group 8

No change: Fourteenth panel of table X W 1
  Fourth character (Body Part) is value 4: Central Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value H: Lovotibeglogene Autotemcel
  Seventh character (Qualifier) is value 9: New Technology Group 9

No change: Fifteenth panel of table X W 1
  Fourth character (Body Part) is value 4: Central Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value J: Exagamglogene Autotemcel
  Seventh character (Qualifier) is value 8: New Technology Group 8

No change: Sixteenth panel of table X W 1
  Fourth character (Body Part) is value 4: Central Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) has 2 choices.
    First choice is value S: Mozafancogene Autotemcel
    Second choice is value Y: Nonautologous (Human) Fibrinogen Concentrate, Shelf-stable
  Seventh character (Qualifier) is value B: New Technology Group 11

No change: table X X E
  First character (Section) is value X: New Technology
  Second character (Body System) is value X: Physiological Systems
  Third character (Operation) is value E: Measurement: Determining the level of a physiological or physical function at a point in time

No change: First panel of table X X E
  Fourth character (Body Part) is value 0: Central Nervous
  Fifth character (Approach) is value X: External
  Sixth character (Device / Substance / Technology) is value 0: Intracranial Vascular Activity, Computer-aided Assessment
  Seventh character (Qualifier) is value 7: New Technology Group 7

No change: Second panel of table X X E
  Fourth character (Body Part) is value 0: Central Nervous
  Fifth character (Approach) is value X: External
  Sixth character (Device / Substance / Technology) is value 1: Intracranial Cerebrospinal Fluid Flow, Computer-aided Triage and Notification
  Seventh character (Qualifier) is value A: New Technology Group 10

No change: Third panel of table X X E
  Fourth character (Body Part) is value 0: Central Nervous
  Fifth character (Approach) is value X: External
  Sixth character (Device / Substance / Technology) is value 4: Brain Electrical Activity, Computer-aided Semiologic Analysis
  Seventh character (Qualifier) is value 8: New Technology Group 8

No change: Fourth panel of table X X E
  Fourth character (Body Part) is value 2: Cardiac
  Fifth character (Approach) is value X: External
  Sixth character (Device / Substance / Technology) is value 1: Output, Computer-aided Assessment
  Seventh character (Qualifier) is value 9: New Technology Group 9

FY2027: Fifth panel of table X X E
  Fourth character (Body Part) is value 2: Cardiac
  Fifth character (Approach) is value X: External
  Sixth character (Device / Substance / Technology) is value H: Cardiac Conduction Mechanism, Computer-aided Mapping for Planning
  Seventh character (Qualifier) is value C: New Technology Group 12

No change: Sixth panel of table X X E
  Fourth character (Body Part) is value 3: Arterial
  Fifth character (Approach) is value X: External
  Sixth character (Device / Substance / Technology) is value 2: Pulmonary Artery Flow, Computer-aided Triage and Notification
  Seventh character (Qualifier) is value 7: New Technology Group 7

No change: Seventh panel of table X X E
  Fourth character (Body Part) is value 3: Arterial
  Fifth character (Approach) is value X: External
  Sixth character (Device / Substance / Technology) has 2 choices.
    First choice is value 5: Coronary Artery Flow, Quantitative Flow Ratio Analysis
    Second choice is value 6: Coronary Artery Flow, Computer-aided Valve Modeling and Notification
  Seventh character (Qualifier) is value 8: New Technology Group 8

No change: Eighth panel of table X X E
  Fourth character (Body Part) is value 5: Circulatory
  Fifth character (Approach) is value X: External
  Sixth character (Device / Substance / Technology) is value 2: Infection, Phenotypic Fully Automated Rapid Susceptibility Technology with Controlled Inoculum
  Seventh character (Qualifier) is value A: New Technology Group 10

No change: Ninth panel of table X X E
  Fourth character (Body Part) is value 5: Circulatory
  Fifth character (Approach) is value X: External
  Sixth character (Device / Substance / Technology) is value 3: Infection, Whole Blood Reverse Transcription and Quantitative Real-time Polymerase Chain Reaction
  Seventh character (Qualifier) is value 8: New Technology Group 8

No change: Tenth panel of table X X E
  Fourth character (Body Part) is value 5: Circulatory
  Fifth character (Approach) is value X: External
  Sixth character (Device / Substance / Technology) has 2 choices.
    First choice is value 4: Infection, Positive Blood Culture Small Molecule Sensor Array Technology
    Second choice is value 5: Immune Response, Whole Blood Cellular Assessment via Microfluidic Deformability
  Seventh character (Qualifier) is value A: New Technology Group 10

No change: Eleventh panel of table X X E
  Fourth character (Body Part) is value 5: Circulatory
  Fifth character (Approach) is value X: External
  Sixth character (Device / Substance / Technology) is value B: Infection and Immune Response, Gene Expression Testing System
  Seventh character (Qualifier) is value B: New Technology Group 11

FY2027: Twelfth panel of table X X E
  Fourth character (Body Part) is value 5: Circulatory
  Fifth character (Approach) is value X: External
  Sixth character (Device / Substance / Technology) is value V: Infection, Serum/Plasma Nanoparticle Fluorescence SARS-CoV-2 Antibody Detection
  Seventh character (Qualifier) is value 7: New Technology Group 7

No change: Thirteenth panel of table X X E
  Fourth character (Body Part) is value 5: Circulatory
  Fifth character (Approach) is value X: External
  Sixth character (Device / Substance / Technology) is value Y: Infection, Other Positive Blood/Isolated Colonies Bimodal Phenotypic Susceptibility Technology
  Seventh character (Qualifier) is value 9: New Technology Group 9

No change: Fourteenth panel of table X X E
  Fourth character (Body Part) is value 9: Nose
  Fifth character (Approach) is value 7: Via Natural or Artificial Opening
  Sixth character (Device / Substance / Technology) is value U: Infection, Nasopharyngeal Fluid SARS-CoV-2 Polymerase Chain Reaction
  Seventh character (Qualifier) is value 7: New Technology Group 7

No change: Fifteenth panel of table X X E
  Fourth character (Body Part) is value Z: None
  Fifth character (Approach) is value X: External
  Sixth character (Device / Substance / Technology) has 2 choices.
    First choice is value A: Macronutrient Content, Computer-aided Assessment for Nutrition Management
    Second choice is value C: Infection, Computer-aided Triage and Notification
  Seventh character (Qualifier) is value B: New Technology Group 11
